<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="other"><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1-3.dtd?><?SourceDTD.Version 1.3?><?ConverterInfo.XSLTName jats2jats3.xsl?><?ConverterInfo.Version 1?><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Antibiotics (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Antibiotics (Basel)</journal-id><journal-id journal-id-type="publisher-id">antibiotics</journal-id><journal-title-group><journal-title>Antibiotics</journal-title></journal-title-group><issn pub-type="epub">2079-6382</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">9495031</article-id><article-id pub-id-type="doi">10.3390/antibiotics11091237</article-id><article-id pub-id-type="publisher-id">antibiotics-11-01237</article-id><article-categories><subj-group subj-group-type="heading"><subject>Perspective</subject></subj-group></article-categories><title-group><article-title>Derivation of a Precise and Consistent Timeline for Antibiotic Development</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6555-1872</contrib-id><name><surname>Stennett</surname><given-names>Henry L.</given-names></name><xref rid="af1-antibiotics-11-01237" ref-type="aff">1</xref><xref rid="af2-antibiotics-11-01237" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9835-9171</contrib-id><name><surname>Back</surname><given-names>Catherine R.</given-names></name><xref rid="af1-antibiotics-11-01237" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0184-5630</contrib-id><name><surname>Race</surname><given-names>Paul R.</given-names></name><xref rid="af1-antibiotics-11-01237" ref-type="aff">1</xref><xref rid="af2-antibiotics-11-01237" ref-type="aff">2</xref><xref rid="c1-antibiotics-11-01237" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Mylonakis</surname><given-names>Eleftherios E.</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-antibiotics-11-01237"><label>1</label>School of Biochemistry, University of Bristol, University Walk, Bristol BS8 1TD, UK</aff><aff id="af2-antibiotics-11-01237"><label>2</label>BrisSynBio Synthetic Biology Research Centre, Tyndall Avenue, Bristol BS8 1TQ, UK</aff><author-notes><corresp id="c1-antibiotics-11-01237"><label>*</label>Correspondence: <email>paul.race@bristol.ac.uk</email></corresp></author-notes><pub-date pub-type="epub"><day>12</day><month>9</month><year>2022</year></pub-date><pub-date pub-type="collection"><month>9</month><year>2022</year></pub-date><volume>11</volume><issue>9</issue><elocation-id>1237</elocation-id><history><date date-type="received"><day>26</day><month>8</month><year>2022</year></date><date date-type="accepted"><day>08</day><month>9</month><year>2022</year></date></history><permissions><copyright-statement>&#x000a9; 2022 by the authors.</copyright-statement><copyright-year>2022</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Antibiotic resistance is a global health crisis. New classes of antibiotics that can treat drug-resistant infections are urgently needed. To communicate this message, researchers have used antibiotic development timelines, but these are often contradictory or imprecise. We conducted a systematic literature review to produce an antibiotic timeline that incorporates the dates of discovery, first use, and initial reports of the emergence of resistance for the 38 classes of clinically used antibiotics. From our timeline, we derive lessons for identifying new antibiotics that are less prone to resistance. These include a required focus on molecules that exhibit multiple modes of action, possess unusually long &#x02018;resistance windows&#x02019;, or those that engage cellular targets whose molecular architectures are at least in part decoupled from evolutionary pressures. Our analysis also further highlights the importance of safeguarding antibiotics as a mechanism for mitigating the development of resistance. We have made our data and sources freely available so that the research community can adapt them to their own needs.</p></abstract><kwd-group><kwd>antibiotic</kwd><kwd>timeline</kwd><kwd>discovery</kwd><kwd>clinical</kwd><kwd>resistance</kwd><kwd>development</kwd></kwd-group><funding-group><award-group><funding-source>BBSRC</funding-source><award-id>BB/T001968/1</award-id><award-id>BB/L01386X/1</award-id></award-group><award-group><funding-source>MRF</funding-source><award-id>MRF-131-0005-RG-RACE-C0853</award-id></award-group><award-group><funding-source>EPSRC Centre for Doctoral Training in Synthetic Biology</funding-source><award-id>EP/L016494/1</award-id></award-group><award-group><funding-source>Dstl</funding-source></award-group><funding-statement>This work was funded by BBSRC grants BB/T001968/1 and BB/L01386X/1, MRF grant MRF-131-0005-RG-RACE-C0853, and through the award of a PhD studentship to H.L.S. from the EPSRC Centre for Doctoral Training in Synthetic Biology (EP/L016494/1) and Dstl.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-antibiotics-11-01237"><title>1. Introduction</title><p>Antibiotic resistance&#x02014;bacterial infections that no longer respond to the drugs used to treat them&#x02014;is a global health crisis of growing concern [<xref rid="B1-antibiotics-11-01237" ref-type="bibr">1</xref>,<xref rid="B2-antibiotics-11-01237" ref-type="bibr">2</xref>]. The demand for existing antibiotics is too high, which drives the evolution of resistance in pathogens [<xref rid="B2-antibiotics-11-01237" ref-type="bibr">2</xref>,<xref rid="B3-antibiotics-11-01237" ref-type="bibr">3</xref>,<xref rid="B4-antibiotics-11-01237" ref-type="bibr">4</xref>]. The supply of new classes of antibiotics that can treat drug-resistant infections is too low, which leaves us with few treatment options for the most serious infections [<xref rid="B5-antibiotics-11-01237" ref-type="bibr">5</xref>,<xref rid="B6-antibiotics-11-01237" ref-type="bibr">6</xref>,<xref rid="B7-antibiotics-11-01237" ref-type="bibr">7</xref>]. To communicate the scale of the problem, researchers have used graphical timelines that show how the rate of antibiotic discovery has slowed in recent times. These timelines are valuable tools for science communication, but often disagree with one another and lack clarity.</p><p>In previous reviews, the definitions used for the date of the discovery of an antibiotic, its first clinical use, and the emergence of resistance to it, either are not disclosed or lack internal consistency. Examples include the non-disclosure of methods used to generate a timeline for antibiotic discovery [<xref rid="B5-antibiotics-11-01237" ref-type="bibr">5</xref>]; inconsistency in the definition of when an antibiotic was introduced into the clinic [<xref rid="B8-antibiotics-11-01237" ref-type="bibr">8</xref>]; not defining the &#x0201c;year of discovery&#x0201d; or &#x0201c;year of introduction&#x0201d; categories and employing a scale with a resolution of decades [<xref rid="B9-antibiotics-11-01237" ref-type="bibr">9</xref>]; and the CDC&#x02019;s 2013 Antibiotic Threats Report, which includes an antibiotic resistance timeline &#x0201c;based on early reports in the literature&#x0201d;, but with a lack of clarity as to whether this refers to in vitro, in vivo, or clinical data [<xref rid="B10-antibiotics-11-01237" ref-type="bibr">10</xref>].</p><p>We conducted a systematic literature review to produce a more precise timeline for antibiotic discovery, introduction, and resistance. Antibiotics can be classified by their origins, structures, and mechanisms of action. We took the 38 classes of antibiotics in clinical use (<xref rid="antibiotics-11-01237-f001" ref-type="fig">Figure 1</xref>), as defined by Hutchings et al. [<xref rid="B8-antibiotics-11-01237" ref-type="bibr">8</xref>], and consistently applied the following definitions to them:<list list-type="order"><list-item><p><bold>Discovery:</bold> when a compound or extract&#x02014;not merely an organism&#x02014;was first reported to have antibiotic activity. In some cases, this was decades after the compound was first discovered or synthesized.</p></list-item><list-item><p><bold>First clinical use:</bold> the first use of the antibiotic to treat a bacterial infection: in modern terms, a phase II trial. Clinical studies of tolerance and toxicity are not included. The approval of an antibiotic for human use is not used because several of these drugs predate regulatory bodies.</p></list-item><list-item><p><bold>Resistance:</bold> the first report of clinically isolated bacteria resistant to the antibiotic.</p></list-item></list></p><p>We hope that our timeline will be a useful resource to the antibiotic research and public health communities. We have included our data and sources so that the timeline can be verified, updated, and modified.</p><fig position="anchor" id="antibiotics-11-01237-f001"><label>Figure 1</label><caption><p>Chemical structures of the 38 classes of antibiotics. (<bold>1</bold>) Arsphenamine in its (<bold>1a</bold>) trivalent and (<bold>1b</bold>) pentavalent forms. General chemical structures of (<bold>2</bold>) a penicillin, (<bold>3</bold>) a sulfonamide, (<bold>4</bold>) a sulphone, (<bold>5</bold>) a polypeptide, (<bold>6</bold>) a salicylate, (<bold>7</bold>) an aminoglycoside, (<bold>8</bold>) a phenazine, (<bold>9</bold>) a nitrofuran, (<bold>10</bold>) a cyclic peptide, (<bold>11</bold>) a cephalosporin, (<bold>12</bold>) an amphenicol, (<bold>13</bold>) a polymyxin, (<bold>14</bold>) an enniatin, (<bold>15</bold>) a tetracycline, (<bold>16</bold>) a diaminopyrimidine, (<bold>17</bold>) a tuberactinomycin, (<bold>18</bold>) a pleuromutilin, (<bold>19</bold>) a macrolide, (<bold>20</bold>) a nicotinamide, (<bold>21</bold>) a streptogramin, (<bold>22</bold>) a thioisonicotinamide, (<bold>23</bold>) a glycopeptide, (<bold>24</bold>) a lincosamide, (<bold>25</bold>) a cycloserine, (<bold>26</bold>) an ansamycin, (<bold>27</bold>) a fusidane, (<bold>28</bold>) a nitroimidazole, (<bold>29</bold>) ethambutol, (<bold>30</bold>) a quinolone, (<bold>31</bold>) a phosphonate, (<bold>32</bold>) a mupirocin, (<bold>33</bold>) a lipiarmycin, (<bold>34</bold>) a carbapenem, (<bold>35</bold>) a monobactam, (<bold>36</bold>) an oxazolidinone, (<bold>37</bold>) a lipopeptide, and (<bold>38</bold>) a diarylquinoline.</p></caption><graphic xlink:href="antibiotics-11-01237-g001a" position="float"/><graphic xlink:href="antibiotics-11-01237-g001b" position="float"/></fig></sec><sec sec-type="results" id="sec2-antibiotics-11-01237"><title>2. Results</title><p><xref rid="antibiotics-11-01237-f002" ref-type="fig">Figure 2</xref> emphasizes the stark reduction in the antibiotic discovery rate after the &#x0201c;Golden Age&#x0201d;, the most prolific period of antibiotic research [<xref rid="B11-antibiotics-11-01237" ref-type="bibr">11</xref>,<xref rid="B12-antibiotics-11-01237" ref-type="bibr">12</xref>]. In fact, the rate of discovery is now at its lowest since the first antibiotic, arsphenamine, was discovered in 1909. The Golden Age is usually roughly defined as 1940&#x02013;1960, beginning with the discovery of streptomycin [<xref rid="B8-antibiotics-11-01237" ref-type="bibr">8</xref>]. Extending the linear part of the sigmoidal discovery curve in <xref rid="antibiotics-11-01237-f001" ref-type="fig">Figure 1</xref> allows us to better define the Golden Age as 1943&#x02013;1962, when streptomycin and the quinolones were discovered, respectively. A 2011 review in <italic toggle="yes">Clinical Microbiology Reviews</italic> defined the &#x0201c;discovery void&#x0201d;, during which no new antibiotic classes have been discovered, as starting from 1987, and several sources have repeated this claim [<xref rid="B5-antibiotics-11-01237" ref-type="bibr">5</xref>,<xref rid="B13-antibiotics-11-01237" ref-type="bibr">13</xref>,<xref rid="B14-antibiotics-11-01237" ref-type="bibr">14</xref>,<xref rid="B15-antibiotics-11-01237" ref-type="bibr">15</xref>]. However, the diarylquinolines were FDA-approved the year after this review, and thus this definition requires revision [<xref rid="B16-antibiotics-11-01237" ref-type="bibr">16</xref>].</p><p><xref rid="antibiotics-11-01237-f003" ref-type="fig">Figure 3</xref> shows the discovery, first clinical use, and resistance dates for the 38 antibiotic classes. From these dates, we can define two periods of time:<list list-type="order"><list-item><p><bold>The development window:</bold> how long after its discovery the antibiotic was first used in the clinic.</p></list-item><list-item><p><bold>The resistance window:</bold> how long after its first use clinical resistance was reported.</p></list-item></list></p><p>There are some obvious outliers in this analysis. The antibiotics with long development windows were either technically challenging to optimize or shelved because they were not considered to be promising drugs until the antibiotic resistance crisis worsened [<xref rid="B17-antibiotics-11-01237" ref-type="bibr">17</xref>,<xref rid="B18-antibiotics-11-01237" ref-type="bibr">18</xref>,<xref rid="B19-antibiotics-11-01237" ref-type="bibr">19</xref>,<xref rid="B20-antibiotics-11-01237" ref-type="bibr">20</xref>]. Five new antibiotic classes have been approved for human use by the FDA in this century: oxazolidinones (2000), lipopeptides (2003), pleuromutilins (2007), diarylquinolones (2007), and lipiarmycins (2011). Three of these were abandoned early in their development because of adverse side effects [<xref rid="B16-antibiotics-11-01237" ref-type="bibr">16</xref>,<xref rid="B17-antibiotics-11-01237" ref-type="bibr">17</xref>,<xref rid="B21-antibiotics-11-01237" ref-type="bibr">21</xref>]. The diarylquinolones carry a black box warning&#x02014;the strongest warning that the FDA requires&#x02014;because of their significant life-threatening side effects [<xref rid="B16-antibiotics-11-01237" ref-type="bibr">16</xref>]. The lipiarmycins and pleuromutilins were first approved for human use long after their discovery: 36 and 56 years, respectively [<xref rid="B17-antibiotics-11-01237" ref-type="bibr">17</xref>,<xref rid="B22-antibiotics-11-01237" ref-type="bibr">22</xref>].</p><p>More promisingly, there are a few examples of antibiotics with unusually long resistance windows, from which we can derive some lessons for designing or identifying &#x0201c;resistance-proof&#x0201d; antibiotics [<xref rid="B23-antibiotics-11-01237" ref-type="bibr">23</xref>,<xref rid="B24-antibiotics-11-01237" ref-type="bibr">24</xref>].</p><fig position="anchor" id="antibiotics-11-01237-f003"><label>Figure 3</label><caption><p>A timeline for the discovery, first clinical use of, and first report of clinical resistance to the 38 classes of antibiotics. For each antibiotic class, the orange bars are the &#x0201c;development windows&#x0201d; and the blue bars are the &#x0201c;resistance windows&#x0201d;.</p></caption><graphic xlink:href="antibiotics-11-01237-g003" position="float"/></fig><sec id="sec2dot1-antibiotics-11-01237"><title>2.1. Multiple Targets</title><p>The polypeptide antibiotic tyrothricin has only been used topically, which is likely part of the reason for its long resistance window [<xref rid="B25-antibiotics-11-01237" ref-type="bibr">25</xref>]. However, even after decades of use, no clinical resistance to the antibiotic has been seen and significant resistance cannot be induced in vitro [<xref rid="B25-antibiotics-11-01237" ref-type="bibr">25</xref>,<xref rid="B26-antibiotics-11-01237" ref-type="bibr">26</xref>]. Wenzel et al. interrogated the antibiotic mechanism of tyrothricin and found that even though its component peptides are highly similar in sequence, they have different mechanisms of action [<xref rid="B27-antibiotics-11-01237" ref-type="bibr">27</xref>]. Their combined effects are to damage DNA, increase membrane permeability, decrease membrane fluidity, and delocalize membrane proteins [<xref rid="B27-antibiotics-11-01237" ref-type="bibr">27</xref>]. This attack on multiple fronts is difficult for bacteria to defend against and makes tyrothricin a natural combination therapy [<xref rid="B28-antibiotics-11-01237" ref-type="bibr">28</xref>]. Clinical phenazine resistance is also extremely rare, although it has been induced in vitro [<xref rid="B29-antibiotics-11-01237" ref-type="bibr">29</xref>,<xref rid="B30-antibiotics-11-01237" ref-type="bibr">30</xref>]. Like tyrothricin, these antibiotics likely have multiple mechanisms of action, which makes resistance more difficult to evolve [<xref rid="B31-antibiotics-11-01237" ref-type="bibr">31</xref>,<xref rid="B32-antibiotics-11-01237" ref-type="bibr">32</xref>]. Identifying new antibiotics with multiple mechanisms of action, or using multiple antibiotics as combination therapies, is likely to slow the development of resistance [<xref rid="B28-antibiotics-11-01237" ref-type="bibr">28</xref>].</p></sec><sec id="sec2dot2-antibiotics-11-01237"><title>2.2. &#x0201c;Resistance-Proof&#x0201d; Targets</title><p>Glycopeptides such as vancomycin bind D-Ala-D-Ala residues at the ends of glycan chains, preventing the binding of peptidoglycan biosynthetic enzymes [<xref rid="B33-antibiotics-11-01237" ref-type="bibr">33</xref>]. This mode of action targets a structural component of the cell that is not directly genetically encoded, so it is difficult to evolve resistance by mutating the target [<xref rid="B34-antibiotics-11-01237" ref-type="bibr">34</xref>]. Furthermore, glycopeptides do not have to enter the cell to act, which means that resistance cannot evolve by reduced permeability to or modification of the antibiotics [<xref rid="B34-antibiotics-11-01237" ref-type="bibr">34</xref>]. Resistance to glycopeptides did not arise in pathogens directly: the self-resistance genes were transferred from the producing microorganisms to pathogens [<xref rid="B34-antibiotics-11-01237" ref-type="bibr">34</xref>]. New antibiotics with similar targets are likely to be &#x0201c;resistance-proof&#x0201d; [<xref rid="B23-antibiotics-11-01237" ref-type="bibr">23</xref>].</p></sec><sec id="sec2dot3-antibiotics-11-01237"><title>2.3. Low Use</title><p>The long resistance window for sulfones is probably due to their main indication as drugs for leprosy [<xref rid="B35-antibiotics-11-01237" ref-type="bibr">35</xref>]. Leprosy is a neglected tropical disease and there are many gaps in our understanding of it [<xref rid="B36-antibiotics-11-01237" ref-type="bibr">36</xref>]. Furthermore, sulfones are only weakly antibacterial against <italic toggle="yes">Mycobacterium leprae</italic>, which made resistance to these antibiotics more difficult to definitively prove [<xref rid="B37-antibiotics-11-01237" ref-type="bibr">37</xref>]. Enniatins are thought to act as ionophores, collapsing ion gradients across membranes in general [<xref rid="B38-antibiotics-11-01237" ref-type="bibr">38</xref>]. In vivo resistance to ionophores has been recorded and can occur by enzymatic degradation or exclusion of the compounds from the cell [<xref rid="B39-antibiotics-11-01237" ref-type="bibr">39</xref>]. Presumably, such mechanisms are also possible for the enniatins, and their limited use due to their cytotoxicity has delayed the onset of resistance [<xref rid="B40-antibiotics-11-01237" ref-type="bibr">40</xref>,<xref rid="B41-antibiotics-11-01237" ref-type="bibr">41</xref>]. The most important lesson for safeguarding antibiotics is that reducing their use will slow the development of resistance [<xref rid="B4-antibiotics-11-01237" ref-type="bibr">4</xref>].</p></sec></sec><sec sec-type="discussion" id="sec3-antibiotics-11-01237"><title>3. Discussion</title><p>This work represents the first comprehensive and consistent timeline for antibiotic discovery, development, and resistance. It should prove useful for communicating the alarmingly low number of new antibiotic classes that are reaching the clinic, and we have also shown how the data can be used to identify antibiotic classes for which resistance is more difficult to evolve. Our findings reveal a correlation between pharmacophore novelty and a reduced &#x02018;development window&#x02019;, and also serve to highlight the importance of prioritizing molecules with expanded &#x02018;resistance windows&#x02019; to ensure the long-term safeguarding of antibiotics. By making our data fully available, and our methods transparent, we hope that future researchers can use and adapt our timeline for their own science communication.</p></sec><sec id="sec4-antibiotics-11-01237"><title>4. Materials and Methods</title><p>We conducted a systematic literature review by searching the Web of Science Core Collection and PubMed databases for the names of antibiotic classes or their first members, and found the earliest dates of discovery, use, and resistance, defined in <xref rid="sec1-antibiotics-11-01237" ref-type="sec">Section 1</xref>. <xref rid="antibiotics-11-01237-t001" ref-type="table">Table 1</xref> shows the data used to make these timelines, with sources for each data point.</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s Note:</bold> MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, H.L.S., C.R.B. and P.R.R.; investigation, H.L.S.; writing&#x02014;original draft preparation, H.L.S.; writing&#x02014;review and editing, C.R.B. and P.R.R.; visualization, H.L.S.; supervision, P.R.R.; funding acquisition, P.R.R. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>No new data were created or analyzed in this study. Data sharing is not applicable to this article.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-antibiotics-11-01237"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Martens</surname><given-names>E.</given-names></name>
<name><surname>Demain</surname><given-names>A.L.</given-names></name>
</person-group><article-title>The antibiotic resistance crisis, with a focus on the United States</article-title><source>J. Antibiot.</source><year>2017</year><volume>70</volume><fpage>520</fpage><lpage>526</lpage><pub-id pub-id-type="doi">10.1038/ja.2017.30</pub-id></element-citation></ref><ref id="B2-antibiotics-11-01237"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ventola</surname><given-names>C.L.</given-names></name>
</person-group><article-title>The antibiotic resistance crisis: Part 1: Causes and threats</article-title><source>Pharm. Ther.</source><year>2015</year><volume>40</volume><fpage>277</fpage><lpage>283</lpage></element-citation></ref><ref id="B3-antibiotics-11-01237"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Klein</surname><given-names>E.Y.</given-names></name>
<name><surname>van Boeckel</surname><given-names>T.P.</given-names></name>
<name><surname>Martinez</surname><given-names>E.M.</given-names></name>
<name><surname>Pant</surname><given-names>S.</given-names></name>
<name><surname>Gandra</surname><given-names>S.</given-names></name>
<name><surname>Levin</surname><given-names>S.A.</given-names></name>
<name><surname>Goossens</surname><given-names>H.</given-names></name>
<name><surname>Laxminarayan</surname><given-names>R.</given-names></name>
</person-group><article-title>Global increase and geographic convergence in antibiotic consumption between 2000 and 2015</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2018</year><volume>115</volume><fpage>E3463</fpage><lpage>E3470</lpage><pub-id pub-id-type="doi">10.1073/pnas.1717295115</pub-id><?supplied-pmid 29581252?><pub-id pub-id-type="pmid">29581252</pub-id></element-citation></ref><ref id="B4-antibiotics-11-01237"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>zur Wiesch</surname><given-names>P.A.</given-names></name>
<name><surname>Kouyos</surname><given-names>R.</given-names></name>
<name><surname>Engelstadter</surname><given-names>J.</given-names></name>
<name><surname>Regoes</surname><given-names>R.R.</given-names></name>
<name><surname>Bonhoeffer</surname><given-names>S.</given-names></name>
</person-group><article-title>Population biological principles of drug-resistance evolution in infectious diseases</article-title><source>Lancet Infect. Dis.</source><year>2011</year><volume>11</volume><fpage>236</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(10)70264-4</pub-id><pub-id pub-id-type="pmid">21371657</pub-id></element-citation></ref><ref id="B5-antibiotics-11-01237"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Silver</surname><given-names>L.L.</given-names></name>
</person-group><article-title>Challenges of antibacterial discovery</article-title><source>Clin. Microbiol. Rev.</source><year>2011</year><volume>24</volume><fpage>71</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1128/CMR.00030-10</pub-id><?supplied-pmid 21233508?><pub-id pub-id-type="pmid">21233508</pub-id></element-citation></ref><ref id="B6-antibiotics-11-01237"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Boucher</surname><given-names>H.W.</given-names></name>
<name><surname>Talbot</surname><given-names>G.H.</given-names></name>
<name><surname>Bradley</surname><given-names>J.S.</given-names></name>
<name><surname>Edwards</surname><given-names>J.E.</given-names></name>
<name><surname>Gilbert</surname><given-names>D.</given-names></name>
<name><surname>Rice</surname><given-names>L.B.</given-names></name>
<name><surname>Scheld</surname><given-names>M.</given-names></name>
<name><surname>Spellberg</surname><given-names>B.</given-names></name>
<name><surname>Bartlett</surname><given-names>J.</given-names></name>
</person-group><article-title>Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America</article-title><source>Clin. Infect. Dis.</source><year>2009</year><volume>48</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1086/595011</pub-id><pub-id pub-id-type="pmid">19035777</pub-id></element-citation></ref><ref id="B7-antibiotics-11-01237"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Theuretzbacher</surname><given-names>U.</given-names></name>
<name><surname>Outterson</surname><given-names>K.</given-names></name>
<name><surname>Engel</surname><given-names>A.</given-names></name>
<name><surname>Karl&#x000e9;n</surname><given-names>A.</given-names></name>
</person-group><article-title>The global preclinical antibacterial pipeline</article-title><source>Nat. Rev. Microbiol.</source><year>2019</year><volume>18</volume><fpage>275</fpage><lpage>285</lpage><pub-id pub-id-type="doi">10.1038/s41579-019-0288-0</pub-id><pub-id pub-id-type="pmid">31745331</pub-id></element-citation></ref><ref id="B8-antibiotics-11-01237"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hutchings</surname><given-names>M.I.</given-names></name>
<name><surname>Truman</surname><given-names>A.W.</given-names></name>
<name><surname>Wilkinson</surname><given-names>B.</given-names></name>
</person-group><article-title>Antibiotics: Past, present and future</article-title><source>Curr. Opin. Microbiol.</source><year>2019</year><volume>51</volume><fpage>72</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1016/j.mib.2019.10.008</pub-id><pub-id pub-id-type="pmid">31733401</pub-id></element-citation></ref><ref id="B9-antibiotics-11-01237"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lewis</surname><given-names>K.</given-names></name>
</person-group><article-title>The science of antibiotic discovery</article-title><source>Cell</source><year>2020</year><volume>181</volume><fpage>29</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.02.056</pub-id><pub-id pub-id-type="pmid">32197064</pub-id></element-citation></ref><ref id="B10-antibiotics-11-01237"><label>10.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>CDC</collab>
</person-group><source>Antibiotic Resistance Threats in the United States</source><publisher-name>U.S. Department for Health and Human Services, Centers for Disease Control and Prevention</publisher-name><publisher-loc>Atlanta, GA, USA</publisher-loc><year>2013</year></element-citation></ref><ref id="B11-antibiotics-11-01237"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shen</surname><given-names>B.</given-names></name>
</person-group><article-title>A new golden age of natural products drug discovery</article-title><source>Cell</source><year>2015</year><volume>163</volume><fpage>1300</fpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.11.031</pub-id></element-citation></ref><ref id="B12-antibiotics-11-01237"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wright</surname><given-names>G.D.</given-names></name>
</person-group><article-title>Unlocking the potential of natural products in drug discovery</article-title><source>Microb. Biotechnol.</source><year>2019</year><volume>12</volume><fpage>55</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1111/1751-7915.13351</pub-id><?supplied-pmid 30565871?><pub-id pub-id-type="pmid">30565871</pub-id></element-citation></ref><ref id="B13-antibiotics-11-01237"><label>13.</label><element-citation publication-type="webpage"><article-title>Few Antibiotics under Development&#x02014;How Did We End up Here?&#x02014;ReAct</article-title><comment>Available online: <ext-link xlink:href="https://www.reactgroup.org/toolbox/understand/how-did-we-end-up-here/few-antibiotics-under-development" ext-link-type="uri">https://www.reactgroup.org/toolbox/understand/how-did-we-end-up-here/few-antibiotics-under-development</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-10-29">(accessed on 29 October 2021)</date-in-citation></element-citation></ref><ref id="B14-antibiotics-11-01237"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Plackett</surname><given-names>B.</given-names></name>
</person-group><article-title>Why big pharma has abandoned antibiotics</article-title><source>Nature</source><year>2020</year><volume>586</volume><fpage>S50</fpage><lpage>S52</lpage><pub-id pub-id-type="doi">10.1038/d41586-020-02884-3</pub-id></element-citation></ref><ref id="B15-antibiotics-11-01237"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nelson</surname><given-names>D.W.</given-names></name>
<name><surname>Moore</surname><given-names>J.E.</given-names></name>
<name><surname>Rao</surname><given-names>J.R.</given-names></name>
</person-group><article-title>Antimicrobial resistance (AMR): Significance to food quality and safety</article-title><source>Food Qual. Saf.</source><year>2019</year><volume>3</volume><fpage>15</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1093/fqsafe/fyz003</pub-id></element-citation></ref><ref id="B16-antibiotics-11-01237"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mahajan</surname><given-names>R.</given-names></name>
</person-group><article-title>Bedaquiline: First FDA-approved tuberculosis drug in 40 years</article-title><source>Int. J. Appl. Basic Med. Res.</source><year>2013</year><volume>3</volume><fpage>1</fpage><lpage>2</lpage><pub-id pub-id-type="doi">10.4103/2229-516X.112228</pub-id><?supplied-pmid 23776831?><pub-id pub-id-type="pmid">23776831</pub-id></element-citation></ref><ref id="B17-antibiotics-11-01237"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Novak</surname><given-names>R.</given-names></name>
</person-group><article-title>Are pleuromutilin antibiotics finally fit for human use?</article-title><source>Ann. N. Y. Acad. Sci.</source><year>2011</year><volume>1241</volume><fpage>71</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1111/j.1749-6632.2011.06219.x</pub-id><?supplied-pmid 22191527?><pub-id pub-id-type="pmid">22191527</pub-id></element-citation></ref><ref id="B18-antibiotics-11-01237"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nation</surname><given-names>R.L.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
</person-group><article-title>Colistin in the 21st Century</article-title><source>Curr. Opin. Infect. Dis.</source><year>2009</year><volume>22</volume><fpage>535</fpage><pub-id pub-id-type="doi">10.1097/QCO.0b013e328332e672</pub-id><pub-id pub-id-type="pmid">19797945</pub-id></element-citation></ref><ref id="B19-antibiotics-11-01237"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Theuretzbacher</surname><given-names>U.</given-names></name>
<name><surname>van Bambeke</surname><given-names>F.</given-names></name>
<name><surname>Cant&#x000f3;n</surname><given-names>R.</given-names></name>
<name><surname>Giske</surname><given-names>C.G.</given-names></name>
<name><surname>Mouton</surname><given-names>J.W.</given-names></name>
<name><surname>Nation</surname><given-names>R.L.</given-names></name>
<name><surname>Paul</surname><given-names>M.</given-names></name>
<name><surname>Turnidge</surname><given-names>J.D.</given-names></name>
<name><surname>Kahlmeter</surname><given-names>G.</given-names></name>
</person-group><article-title>Reviving old antibiotics</article-title><source>J. Antimicrob. Chemother.</source><year>2015</year><volume>70</volume><fpage>2177</fpage><lpage>2181</lpage><pub-id pub-id-type="doi">10.1093/jac/dkv157</pub-id><pub-id pub-id-type="pmid">26063727</pub-id></element-citation></ref><ref id="B20-antibiotics-11-01237"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bergen</surname><given-names>P.J.</given-names></name>
<name><surname>Landersdorfer</surname><given-names>C.B.</given-names></name>
<name><surname>Lee</surname><given-names>H.J.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Nation</surname><given-names>R.L.</given-names></name>
</person-group><article-title>&#x02018;Old&#x02019; antibiotics for emerging multidrug-resistant bacteria</article-title><source>Curr. Opin. Infect. Dis.</source><year>2012</year><volume>25</volume><fpage>626</fpage><lpage>633</lpage><pub-id pub-id-type="doi">10.1097/QCO.0b013e328358afe5</pub-id><pub-id pub-id-type="pmid">23041772</pub-id></element-citation></ref><ref id="B21-antibiotics-11-01237"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tally</surname><given-names>F.P.</given-names></name>
<name><surname>DeBruin</surname><given-names>M.F.</given-names></name>
</person-group><article-title>Development of daptomycin for Gram-positive infections</article-title><source>J. Antimicrob. Chemother.</source><year>2000</year><volume>46</volume><fpage>523</fpage><lpage>526</lpage><pub-id pub-id-type="doi">10.1093/jac/46.4.523</pub-id><pub-id pub-id-type="pmid">11020247</pub-id></element-citation></ref><ref id="B22-antibiotics-11-01237"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McAlpine</surname><given-names>J.B.</given-names></name>
</person-group><article-title>The ups and downs of drug discovery: The early history of Fidaxomicin</article-title><source>J. Antibiot.</source><year>2017</year><volume>70</volume><fpage>492</fpage><lpage>494</lpage><pub-id pub-id-type="doi">10.1038/ja.2016.157</pub-id></element-citation></ref><ref id="B23-antibiotics-11-01237"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wu</surname><given-names>Z.C.</given-names></name>
<name><surname>Boger</surname><given-names>D.L.</given-names></name>
</person-group><article-title>Maxamycins: Durable antibiotics derived by rational redesign of vancomycin</article-title><source>Acc. Chem. Res.</source><year>2020</year><volume>53</volume><fpage>2587</fpage><lpage>2599</lpage><pub-id pub-id-type="doi">10.1021/acs.accounts.0c00569</pub-id><?supplied-pmid 33138354?><pub-id pub-id-type="pmid">33138354</pub-id></element-citation></ref><ref id="B24-antibiotics-11-01237"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Oldfield</surname><given-names>E.</given-names></name>
<name><surname>Feng</surname><given-names>X.</given-names></name>
</person-group><article-title>Resistance-resistant antibiotics</article-title><source>Trends Pharmacol. Sci.</source><year>2014</year><volume>35</volume><fpage>664</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2014.10.007</pub-id><?supplied-pmid 25458541?><pub-id pub-id-type="pmid">25458541</pub-id></element-citation></ref><ref id="B25-antibiotics-11-01237"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lang</surname><given-names>C.</given-names></name>
<name><surname>Staiger</surname><given-names>C.</given-names></name>
</person-group><article-title>Tyrothricin&#x02014;An underrated agent for the treatment of bacterial skin infections and superficial wounds?</article-title><source>Pharmazie</source><year>2016</year><volume>71</volume><fpage>299</fpage><lpage>305</lpage><?supplied-pmid 27455547?><pub-id pub-id-type="pmid">27455547</pub-id></element-citation></ref><ref id="B26-antibiotics-11-01237"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stauss-Grabo</surname><given-names>M.</given-names></name>
<name><surname>Atiye</surname><given-names>S.</given-names></name>
<name><surname>Kretschmar</surname><given-names>M.</given-names></name>
</person-group><article-title>Decade-long use of the antimicrobial peptide combination tyrothricin does not pose a major risk of acquired resistance with Gram-positive bacteria and <italic toggle="yes">Candida</italic> spp</article-title><source>Pharmazie</source><year>2014</year><volume>69</volume><fpage>838</fpage><lpage>841</lpage><?supplied-pmid 25985581?><pub-id pub-id-type="pmid">25985581</pub-id></element-citation></ref><ref id="B27-antibiotics-11-01237"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wenzel</surname><given-names>M.</given-names></name>
<name><surname>Rautenbach</surname><given-names>M.</given-names></name>
<name><surname>Voslo</surname><given-names>J.A.</given-names></name>
<name><surname>Siersma</surname><given-names>T.</given-names></name>
<name><surname>Aisenbrey</surname><given-names>C.H.M.</given-names></name>
<name><surname>Zaitseva</surname><given-names>E.</given-names></name>
<name><surname>Laubscher</surname><given-names>W.E.</given-names></name>
<name><surname>van Rensburg</surname><given-names>W.</given-names></name>
<name><surname>Behrends</surname><given-names>J.C.</given-names></name>
<name><surname>Bechinger</surname><given-names>B.</given-names></name>
<etal/>
</person-group><article-title>The Multifaceted Antibacterial Mechanisms of the Pioneering Peptide Antibiotics Tyrocidine and Gramicidin S</article-title><source>mBio</source><year>2018</year><volume>9</volume><fpage>e00802</fpage><lpage>e00818</lpage><pub-id pub-id-type="doi">10.1128/mBio.00802-18</pub-id><?supplied-pmid 30301848?><pub-id pub-id-type="pmid">30301848</pub-id></element-citation></ref><ref id="B28-antibiotics-11-01237"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Coates</surname><given-names>A.R.M.</given-names></name>
<name><surname>Hu</surname><given-names>Y.</given-names></name>
<name><surname>Holt</surname><given-names>J.</given-names></name>
<name><surname>Yeh</surname><given-names>P.</given-names></name>
</person-group><article-title>Antibiotic combination therapy against resistant bacterial infections: Synergy, rejuvenation and resistance reduction</article-title><source>Expert Rev. Anti-Infect. Ther.</source><year>2020</year><volume>18</volume><fpage>5</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1080/14787210.2020.1705155</pub-id><pub-id pub-id-type="pmid">31847614</pub-id></element-citation></ref><ref id="B29-antibiotics-11-01237"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hartkoorn</surname><given-names>R.C.</given-names></name>
<name><surname>Uplekar</surname><given-names>S.</given-names></name>
<name><surname>Cole</surname><given-names>S.T.</given-names></name>
</person-group><article-title>Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in <italic toggle="yes">Mycobacterium tuberculosis</italic></article-title><source>Antimicrob. Agents Chemother.</source><year>2014</year><volume>58</volume><fpage>2979</fpage><lpage>2981</lpage><pub-id pub-id-type="doi">10.1128/AAC.00037-14</pub-id><pub-id pub-id-type="pmid">24590481</pub-id></element-citation></ref><ref id="B30-antibiotics-11-01237"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fu</surname><given-names>T.</given-names></name>
<name><surname>Cai</surname><given-names>Z.</given-names></name>
<name><surname>Yue</surname><given-names>Z.</given-names></name>
<name><surname>Yang</surname><given-names>H.</given-names></name>
<name><surname>Fang</surname><given-names>B.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Fan</surname><given-names>Z.</given-names></name>
<name><surname>Pan</surname><given-names>X.</given-names></name>
<name><surname>Yang</surname><given-names>F.</given-names></name>
<name><surname>Jin</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>Evolution of resistance to phenazine antibiotics in <italic toggle="yes">Staphylococcus aureus</italic> and its role during coinfection with <italic toggle="yes">Pseudomonas aeruginosa</italic></article-title><source>ACS Infect. Dis.</source><year>2021</year><volume>7</volume><fpage>636</fpage><lpage>649</lpage><pub-id pub-id-type="doi">10.1021/acsinfecdis.0c00837</pub-id><pub-id pub-id-type="pmid">33650853</pub-id></element-citation></ref><ref id="B31-antibiotics-11-01237"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cholo</surname><given-names>M.C.</given-names></name>
<name><surname>Steel</surname><given-names>H.C.</given-names></name>
<name><surname>Fourie</surname><given-names>P.B.</given-names></name>
<name><surname>Germishuizen</surname><given-names>W.A.</given-names></name>
<name><surname>Anderson</surname><given-names>R.</given-names></name>
</person-group><article-title>Clofazimine: Current status and future prospects</article-title><source>J. Antimicrob. Chemother.</source><year>2012</year><volume>67</volume><fpage>290</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1093/jac/dkr444</pub-id><pub-id pub-id-type="pmid">22020137</pub-id></element-citation></ref><ref id="B32-antibiotics-11-01237"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Guttenberger</surname><given-names>N.</given-names></name>
<name><surname>Blankenfeldt</surname><given-names>W.</given-names></name>
<name><surname>Breinbauer</surname><given-names>R.</given-names></name>
</person-group><article-title>Recent developments in the isolation, biological function, biosynthesis, and synthesis of phenazine natural products</article-title><source>Bioorg. Med. Chem.</source><year>2017</year><volume>25</volume><fpage>6149</fpage><lpage>6166</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2017.01.002</pub-id><pub-id pub-id-type="pmid">28094222</pub-id></element-citation></ref><ref id="B33-antibiotics-11-01237"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Barna</surname><given-names>J.C.</given-names></name>
<name><surname>Williams</surname><given-names>D.H.</given-names></name>
</person-group><article-title>The structure and mode of action of glycopeptide antibiotics of the vancomycin group</article-title><source>Annu. Rev. Microbiol.</source><year>1984</year><volume>38</volume><fpage>339</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1146/annurev.mi.38.100184.002011</pub-id><pub-id pub-id-type="pmid">6388496</pub-id></element-citation></ref><ref id="B34-antibiotics-11-01237"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kahne</surname><given-names>D.</given-names></name>
<name><surname>Leimkuhler</surname><given-names>C.</given-names></name>
<name><surname>Lu</surname><given-names>W.</given-names></name>
<name><surname>Walsh</surname><given-names>C.</given-names></name>
</person-group><article-title>Glycopeptide and lipoglycopeptide antibiotics</article-title><source>Chem. Rev.</source><year>2005</year><volume>105</volume><fpage>425</fpage><lpage>448</lpage><pub-id pub-id-type="doi">10.1021/cr030103a</pub-id><?supplied-pmid 15700951?><pub-id pub-id-type="pmid">15700951</pub-id></element-citation></ref><ref id="B35-antibiotics-11-01237"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pearson</surname><given-names>J.M.</given-names></name>
<name><surname>Rees</surname><given-names>R.J.</given-names></name>
<name><surname>Waters</surname><given-names>M.F.</given-names></name>
</person-group><article-title>Sulphone resistance in leprosy. A review of one hundred proven clinical cases</article-title><source>Lancet</source><year>1975</year><volume>2</volume><fpage>69</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(75)90508-5</pub-id><pub-id pub-id-type="pmid">49662</pub-id></element-citation></ref><ref id="B36-antibiotics-11-01237"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Molyneux</surname><given-names>D.</given-names></name>
</person-group><article-title>Neglected tropical diseases</article-title><source>Community Eye Health</source><year>2013</year><volume>26</volume><fpage>21</fpage><lpage>24</lpage><?supplied-pmid 24023397?><pub-id pub-id-type="pmid">24023397</pub-id></element-citation></ref><ref id="B37-antibiotics-11-01237"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Prasad</surname><given-names>P.V.S.</given-names></name>
<name><surname>Kaviarasan</surname><given-names>P.K.</given-names></name>
</person-group><article-title>Leprosy therapy, past and present: Can we hope to eliminate it?</article-title><source>Indian J. Dermatol.</source><year>2010</year><volume>55</volume><fpage>316</fpage><lpage>324</lpage><pub-id pub-id-type="doi">10.4103/0019-5154.74528</pub-id><?supplied-pmid 21430881?><pub-id pub-id-type="pmid">21430881</pub-id></element-citation></ref><ref id="B38-antibiotics-11-01237"><label>38.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Bakker</surname><given-names>E.P.</given-names></name>
</person-group><article-title>Ionophore Antibiotics</article-title><source>Mechanism of Action of Antibacterial Agents</source><edition>2nd ed.</edition><person-group person-group-type="editor">
<name><surname>Hahn</surname><given-names>F.E.</given-names></name>
</person-group><publisher-name>Springer</publisher-name><publisher-loc>Berlin/Heidelberg, Germany</publisher-loc><year>1979</year><volume>Volume 5</volume><fpage>67</fpage><lpage>97</lpage></element-citation></ref><ref id="B39-antibiotics-11-01237"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Russell</surname><given-names>J.B.</given-names></name>
<name><surname>Houlihan</surname><given-names>A.J.</given-names></name>
</person-group><article-title>Ionophore resistance of ruminal bacteria and its potential impact on human health</article-title><source>FEMS Microbiol. Rev.</source><year>2003</year><volume>27</volume><fpage>65</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1016/S0168-6445(03)00019-6</pub-id><pub-id pub-id-type="pmid">12697342</pub-id></element-citation></ref><ref id="B40-antibiotics-11-01237"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Olleik</surname><given-names>H.</given-names></name>
<name><surname>Nicoletti</surname><given-names>C.</given-names></name>
<name><surname>Lafond</surname><given-names>M.</given-names></name>
<name><surname>Courvoisier-Dezord</surname><given-names>E.</given-names></name>
<name><surname>Xue</surname><given-names>P.</given-names></name>
<name><surname>Hijazi</surname><given-names>A.</given-names></name>
<name><surname>Baydoun</surname><given-names>E.</given-names></name>
<name><surname>Perrier</surname><given-names>J.</given-names></name>
<name><surname>Maresca</surname><given-names>M.</given-names></name>
</person-group><article-title>Comparative structure-activity analysis of the antimicrobial activity, cytotoxicity, and mechanism of action of the fungal cyclohexadepsipeptides enniatins and beauvericin</article-title><source>Toxins</source><year>2019</year><volume>11</volume><elocation-id>514</elocation-id><pub-id pub-id-type="doi">10.3390/toxins11090514</pub-id></element-citation></ref><ref id="B41-antibiotics-11-01237"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>German-Fattal</surname><given-names>M.</given-names></name>
</person-group><article-title>Fusafungine, an antimicrobial with anti-inflammatory properties in respiratory tract infections</article-title><source>Clin. Drug Investig.</source><year>2001</year><volume>21</volume><fpage>653</fpage><lpage>670</lpage><pub-id pub-id-type="doi">10.2165/00044011-200121090-00007</pub-id></element-citation></ref><ref id="B42-antibiotics-11-01237"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rubin</surname><given-names>R.P.</given-names></name>
</person-group><article-title>A brief history of great discoveries in pharmacology: In celebration of the centennial anniversary of the founding of the American Society of Pharmacology and Experimental Therapeutics</article-title><source>Pharmacol. Rev.</source><year>2007</year><volume>59</volume><fpage>289</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.1124/pr.107.70102</pub-id><pub-id pub-id-type="pmid">18160700</pub-id></element-citation></ref><ref id="B43-antibiotics-11-01237"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Williams</surname><given-names>K.</given-names></name>
</person-group><article-title>The introduction of &#x02018;chemotherapy&#x02019; using arsphenamine&#x02014;The first magic bullet</article-title><source>J. R. Soc. Med.</source><year>2009</year><volume>102</volume><fpage>343</fpage><pub-id pub-id-type="doi">10.1258/jrsm.2009.09k036</pub-id><pub-id pub-id-type="pmid">19679737</pub-id></element-citation></ref><ref id="B44-antibiotics-11-01237"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tan</surname><given-names>S.Y.</given-names></name>
<name><surname>Tatsumura</surname><given-names>Y.</given-names></name>
</person-group><article-title>Alexander Fleming (1881&#x02013;1955): Discoverer of penicillin</article-title><source>Singap. Med. J.</source><year>2015</year><volume>56</volume><fpage>366</fpage><pub-id pub-id-type="doi">10.11622/smedj.2015105</pub-id><?supplied-pmid 26243971?><pub-id pub-id-type="pmid">26243971</pub-id></element-citation></ref><ref id="B45-antibiotics-11-01237"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fletcher</surname><given-names>C.</given-names></name>
</person-group><article-title>First clinical use of penicillin</article-title><source>Br. Med. J.</source><year>1984</year><volume>289</volume><fpage>1721</fpage><pub-id pub-id-type="doi">10.1136/bmj.289.6460.1721</pub-id><?supplied-pmid 6440620?><pub-id pub-id-type="pmid">6440620</pub-id></element-citation></ref><ref id="B46-antibiotics-11-01237"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Plough</surname><given-names>H.H.</given-names></name>
</person-group><article-title>Penicillin resistance of <italic toggle="yes">Staphylococcus aureus</italic> and its clinical implications</article-title><source>Am. J. Clin. Pathol.</source><year>1945</year><volume>15</volume><fpage>446</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.1093/ajcp/15.10.446</pub-id><pub-id pub-id-type="pmid">21005048</pub-id></element-citation></ref><ref id="B47-antibiotics-11-01237"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Domagk</surname><given-names>G.</given-names></name>
</person-group><article-title>Chemotherapie der bakteriellen infektionen</article-title><source>Angew. Chem.</source><year>1935</year><volume>48</volume><fpage>657</fpage><lpage>667</lpage><pub-id pub-id-type="doi">10.1002/ange.19350484202</pub-id></element-citation></ref><ref id="B48-antibiotics-11-01237"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Maclean</surname><given-names>I.</given-names></name>
<name><surname>Rogers</surname><given-names>K.</given-names></name>
<name><surname>Fleming</surname><given-names>A.</given-names></name>
</person-group><article-title>M. &#x00026; B. 693 and pneumococci</article-title><source>Lancet</source><year>1939</year><volume>233</volume><fpage>562</fpage><lpage>568</lpage></element-citation></ref><ref id="B49-antibiotics-11-01237"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wozel</surname><given-names>G.</given-names></name>
</person-group><article-title>The story of sulfones in tropical medicine and dermatology</article-title><source>Int. J. Dermatol.</source><year>1989</year><volume>28</volume><fpage>17</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1111/j.1365-4362.1989.tb01301.x</pub-id><pub-id pub-id-type="pmid">2645226</pub-id></element-citation></ref><ref id="B50-antibiotics-11-01237"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Faget</surname><given-names>G.H.</given-names></name>
<name><surname>Pogge</surname><given-names>R.C.</given-names></name>
<name><surname>Johansen</surname><given-names>F.A.</given-names></name>
<name><surname>Dinan</surname><given-names>J.F.</given-names></name>
<name><surname>Prejean</surname><given-names>B.M.</given-names></name>
<name><surname>Eccles</surname><given-names>C.G.</given-names></name>
</person-group><article-title>The promin treatment of leprosy. A progress report</article-title><source>Public Health Rep.</source><year>1943</year><volume>58</volume><fpage>1729</fpage><pub-id pub-id-type="doi">10.2307/4584691</pub-id><pub-id pub-id-type="pmid">19315949</pub-id></element-citation></ref><ref id="B51-antibiotics-11-01237"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dubos</surname><given-names>R.J.</given-names></name>
</person-group><article-title>Studies on a bactericidal agent extracted from a soil <italic toggle="yes">Bacillus</italic>: I. Preparation of the agent. Its activity <italic toggle="yes">in vitro</italic></article-title><source>J. Exp. Med.</source><year>1939</year><volume>70</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1084/jem.70.1.1</pub-id><pub-id pub-id-type="pmid">19870884</pub-id></element-citation></ref><ref id="B52-antibiotics-11-01237"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Herrell</surname><given-names>W.E.</given-names></name>
<name><surname>Heilman</surname><given-names>D.</given-names></name>
</person-group><article-title>Experimental and clinical studies on gramicidin</article-title><source>J. Clin. Investig.</source><year>1941</year><volume>20</volume><fpage>583</fpage><pub-id pub-id-type="doi">10.1172/JCI101251</pub-id><pub-id pub-id-type="pmid">16694863</pub-id></element-citation></ref><ref id="B53-antibiotics-11-01237"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bernheim</surname><given-names>F.</given-names></name>
</person-group><article-title>The effect of salicylate on the oxygen uptake of the tubercle bacillus</article-title><source>Science</source><year>1940</year><volume>92</volume><fpage>204</fpage><pub-id pub-id-type="doi">10.1126/science.92.2383.204.a</pub-id></element-citation></ref><ref id="B54-antibiotics-11-01237"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lehmann</surname><given-names>J.</given-names></name>
</person-group><article-title>Para-aminosalicylic acid in the treatment of tuberculosis</article-title><source>Lancet</source><year>1946</year><volume>1</volume><fpage>15</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(46)91185-3</pub-id><pub-id pub-id-type="pmid">21008766</pub-id></element-citation></ref><ref id="B55-antibiotics-11-01237"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<collab>A Medical Research Council Investigation</collab>
</person-group><article-title>Treatment of pulmonary tuberculosis with streptomycin and para-amino-salicylic acid</article-title><source>Br. Med. J.</source><year>1950</year><volume>2</volume><fpage>1073</fpage><lpage>1085</lpage><pub-id pub-id-type="doi">10.1136/bmj.2.4688.1073</pub-id><pub-id pub-id-type="pmid">14772553</pub-id></element-citation></ref><ref id="B56-antibiotics-11-01237"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rawlins</surname><given-names>M.</given-names></name>
</person-group><article-title>The disputed discovery of streptomycin</article-title><source>Lancet</source><year>2012</year><volume>380</volume><fpage>207</fpage><pub-id pub-id-type="doi">10.1016/S0140-6736(12)61202-1</pub-id></element-citation></ref><ref id="B57-antibiotics-11-01237"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Crofton</surname><given-names>J.</given-names></name>
</person-group><article-title>The MRC randomized trial of streptomycin and its legacy: A view from the clinical front line</article-title><source>J. R. Soc. Med.</source><year>2006</year><volume>99</volume><fpage>531</fpage><pub-id pub-id-type="doi">10.1177/014107680609901017</pub-id><?supplied-pmid 17021304?><pub-id pub-id-type="pmid">17021304</pub-id></element-citation></ref><ref id="B58-antibiotics-11-01237"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Finland</surname><given-names>M.</given-names></name>
<name><surname>Murray</surname><given-names>R.</given-names></name>
</person-group><article-title>Development of streptomycin resistance during treatment</article-title><source>J. Am. Med. Assoc.</source><year>1946</year><volume>132</volume><fpage>16</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1001/jama.1946.02870360018005</pub-id><?supplied-pmid 20995215?><pub-id pub-id-type="pmid">20995215</pub-id></element-citation></ref><ref id="B59-antibiotics-11-01237"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Carr</surname><given-names>C.J.</given-names></name>
<name><surname>Vivian</surname><given-names>D.L.</given-names></name>
<name><surname>Krantz</surname><given-names>J.C.</given-names></name>
</person-group><article-title>A contribution to the pharmacology of phenazine and certain of its derivatives</article-title><source>J. Pharmacol. Exp. Ther.</source><year>1943</year><volume>77</volume><fpage>215</fpage><lpage>219</lpage></element-citation></ref><ref id="B60-antibiotics-11-01237"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Browne</surname><given-names>S.G.</given-names></name>
<name><surname>Hogerzeil</surname><given-names>L.M.</given-names></name>
</person-group><article-title>&#x0201c;B 663&#x0201d; in the treatment of leprosy. Preliminary report of a pilot trial</article-title><source>Lepr. Rev.</source><year>1962</year><volume>33</volume><fpage>6</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.5935/0305-7518.19620002</pub-id><pub-id pub-id-type="pmid">13873759</pub-id></element-citation></ref><ref id="B61-antibiotics-11-01237"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Andries</surname><given-names>K.</given-names></name>
<name><surname>Villellas</surname><given-names>C.</given-names></name>
<name><surname>Coeck</surname><given-names>N.</given-names></name>
<name><surname>Thys</surname><given-names>K.</given-names></name>
<name><surname>Gevers</surname><given-names>T.</given-names></name>
<name><surname>Vranckx</surname><given-names>L.</given-names></name>
<name><surname>Lounis</surname><given-names>N.</given-names></name>
<name><surname>de Jong</surname><given-names>B.C.</given-names></name>
<name><surname>Koul</surname><given-names>A.</given-names></name>
</person-group><article-title>Acquired Resistance of <italic toggle="yes">Mycobacterium tuberculosis</italic> to bedaquiline</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e102135</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0102135</pub-id><pub-id pub-id-type="pmid">25010492</pub-id></element-citation></ref><ref id="B62-antibiotics-11-01237"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dodd</surname><given-names>M.C.</given-names></name>
<name><surname>Stillman</surname><given-names>W.B.</given-names></name>
<name><surname>Roys</surname><given-names>M.</given-names></name>
<name><surname>Crosby</surname><given-names>C.</given-names></name>
</person-group><article-title>The in vitro bacteriostatic action of some simple furan derivatives</article-title><source>J. Pharmacol. Exp. Ther.</source><year>1944</year><volume>82</volume><fpage>11</fpage><lpage>18</lpage></element-citation></ref><ref id="B63-antibiotics-11-01237"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dodd</surname><given-names>M.C.</given-names></name>
<name><surname>Hartmann</surname><given-names>F.W.</given-names></name>
<name><surname>Ward</surname><given-names>W.C.</given-names></name>
</person-group><article-title>The local application of nitrofuran compounds with special reference to use on wounds</article-title><source>Surg. Gynecol. Obstet.</source><year>1946</year><volume>83</volume><fpage>73</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">20988040</pub-id></element-citation></ref><ref id="B64-antibiotics-11-01237"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lutz</surname><given-names>A.</given-names></name>
<name><surname>Witz</surname><given-names>M.</given-names></name>
<name><surname>Schaeffer</surname><given-names>A.</given-names></name>
</person-group><article-title>Recherches sur l&#x02019;&#x000e9;volution de la r&#x000e9;sistance de germes du genre proteus aux antibiotiques usuels de 1950 &#x000e0; 1958; l&#x02019;action <italic toggle="yes">in vitro</italic> de la novobiocine, de la kanamycine, de la nitrofurantoine, et des sulfamides</article-title><source>Ann. Inst. Pasteur</source><year>1958</year><volume>95</volume><fpage>413</fpage><lpage>423</lpage><pub-id pub-id-type="pmid">13583664</pub-id></element-citation></ref><ref id="B65-antibiotics-11-01237"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Johnson</surname><given-names>B.A.</given-names></name>
<name><surname>Anker</surname><given-names>H.</given-names></name>
<name><surname>Meleney</surname><given-names>F.L.</given-names></name>
</person-group><article-title>Bacitracin: A new antibiotic produced by a member of the <italic toggle="yes">B. subtilis</italic> group</article-title><source>Science</source><year>1945</year><volume>102</volume><fpage>376</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.1126/science.102.2650.376</pub-id><?supplied-pmid 17770204?><pub-id pub-id-type="pmid">17770204</pub-id></element-citation></ref><ref id="B66-antibiotics-11-01237"><label>66.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Nguyen</surname><given-names>R.</given-names></name>
<name><surname>Khanna</surname><given-names>N.R.</given-names></name>
<name><surname>Safadi</surname><given-names>A.O.</given-names></name>
<name><surname>Sun</surname><given-names>Y.</given-names></name>
</person-group><article-title>Bacitracin Topical</article-title><source>StatPearls</source><publisher-name>StatPearls Publishing</publisher-name><publisher-loc>Treasure Island, FL, USA</publisher-loc><year>2021</year></element-citation></ref><ref id="B67-antibiotics-11-01237"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stone</surname><given-names>J.L.</given-names></name>
</person-group><article-title>Induced resistance to bacitracin in cultures of <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>J. Infect. Dis.</source><year>1949</year><volume>85</volume><fpage>91</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1093/infdis/85.1.91</pub-id><pub-id pub-id-type="pmid">18132374</pub-id></element-citation></ref><ref id="B68-antibiotics-11-01237"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abraham</surname><given-names>E.P.</given-names></name>
</person-group><article-title>A glimpse of the early history of the cephalosporins</article-title><source>Rev. Infect. Dis.</source><year>1979</year><volume>1</volume><fpage>99</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1093/clinids/1.1.99</pub-id><?supplied-pmid 400942?><pub-id pub-id-type="pmid">400942</pub-id></element-citation></ref><ref id="B69-antibiotics-11-01237"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bastin</surname><given-names>R.</given-names></name>
<name><surname>Worms</surname><given-names>R.</given-names></name>
<name><surname>Acar</surname><given-names>J.F.</given-names></name>
</person-group><article-title>Clinical incidence of heterogenous resistance of <italic toggle="yes">Staphylococcus</italic> to penicillin and cephalosporin</article-title><source>Pathol. Biol.</source><year>1967</year><volume>15</volume><fpage>1205</fpage><lpage>1211</lpage><?supplied-pmid 4867326?><pub-id pub-id-type="pmid">4867326</pub-id></element-citation></ref><ref id="B70-antibiotics-11-01237"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ehrlich</surname><given-names>J.</given-names></name>
<name><surname>Bartz</surname><given-names>Q.R.</given-names></name>
<name><surname>Smith</surname><given-names>R.M.</given-names></name>
<name><surname>Joslyn</surname><given-names>D.A.</given-names></name>
<name><surname>Burkholder</surname><given-names>P.R.</given-names></name>
</person-group><article-title>Chloromycetin, a new antibiotic from a soil actinomycete</article-title><source>Science</source><year>1947</year><volume>106</volume><fpage>417</fpage><pub-id pub-id-type="doi">10.1126/science.106.2757.417</pub-id><pub-id pub-id-type="pmid">17737966</pub-id></element-citation></ref><ref id="B71-antibiotics-11-01237"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Smadel</surname><given-names>J.E.</given-names></name>
</person-group><article-title>Clinical use of the antibiotic chloramphenicol (chloromycetin<sup>&#x000ae;</sup>)</article-title><source>J. Am. Med. Assoc.</source><year>1950</year><volume>142</volume><fpage>315</fpage><lpage>318</lpage><pub-id pub-id-type="doi">10.1001/jama.1950.02910230017004</pub-id><pub-id pub-id-type="pmid">15401448</pub-id></element-citation></ref><ref id="B72-antibiotics-11-01237"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Colquhoun</surname><given-names>J.</given-names></name>
<name><surname>Weetch</surname><given-names>R.S.</given-names></name>
</person-group><article-title>Resistance to chloramphenicol developing during treatment of typhoid fever</article-title><source>Lancet</source><year>1950</year><volume>256</volume><fpage>621</fpage><lpage>623</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(50)91585-6</pub-id></element-citation></ref><ref id="B73-antibiotics-11-01237"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ainsworth</surname><given-names>G.C.</given-names></name>
<name><surname>Brown</surname><given-names>A.M.</given-names></name>
<name><surname>Brownlee</surname><given-names>G.</given-names></name>
</person-group><article-title>&#x02018;Aerosporin&#x02019;, an antibiotic produced by <italic toggle="yes">Bacillus aerosporus</italic> Greer</article-title><source>Nature</source><year>1947</year><volume>160</volume><fpage>263</fpage><pub-id pub-id-type="doi">10.1038/160263a0</pub-id></element-citation></ref><ref id="B74-antibiotics-11-01237"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schoenbach</surname><given-names>E.B.</given-names></name>
<name><surname>Bryer</surname><given-names>M.S.</given-names></name>
</person-group><article-title>Polymyxin; A note on experimental and clinical investigations</article-title><source>J. Am. Med. Assoc.</source><year>1948</year><volume>136</volume><fpage>1096</fpage><lpage>1098</lpage><pub-id pub-id-type="doi">10.1001/jama.1948.02890340022007</pub-id><pub-id pub-id-type="pmid">18857027</pub-id></element-citation></ref><ref id="B75-antibiotics-11-01237"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hirsch</surname><given-names>H.A.</given-names></name>
<name><surname>McCarthy</surname><given-names>C.G.</given-names></name>
<name><surname>Finland</surname><given-names>M.</given-names></name>
</person-group><article-title>Polymyxin B and colistin: Activity, resistance and crossresistance in vitro</article-title><source>Proc. Soc. Exp. Biol. Med.</source><year>1960</year><volume>103</volume><fpage>338</fpage><lpage>342</lpage><pub-id pub-id-type="doi">10.3181/00379727-103-25511</pub-id><?supplied-pmid 14401972?><pub-id pub-id-type="pmid">14401972</pub-id></element-citation></ref><ref id="B76-antibiotics-11-01237"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gaumann</surname><given-names>E.</given-names></name>
<name><surname>Roth</surname><given-names>S.</given-names></name>
</person-group><article-title>Enniatin, a new antibiotic that works against mycobacteria</article-title><source>Experientia</source><year>1947</year><volume>3</volume><fpage>202</fpage><lpage>203</lpage><?supplied-pmid 20254435?><pub-id pub-id-type="pmid">20254435</pub-id></element-citation></ref><ref id="B77-antibiotics-11-01237"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Piquet</surname><given-names>J.J.</given-names></name>
<name><surname>Hequet</surname><given-names>B.</given-names></name>
<name><surname>Decroix</surname><given-names>G.</given-names></name>
</person-group><article-title>Value of the use of locabiotal pressurise in rhinosinus pathology in children</article-title><source>Lille M&#x000e9;d.</source><year>1968</year><volume>14</volume><fpage>S497</fpage><lpage>S499</lpage></element-citation></ref><ref id="B78-antibiotics-11-01237"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>German-Fattal</surname><given-names>M.</given-names></name>
</person-group><article-title>Fusafungine. An antimicrobial agent for the local treatment of respiratory tract infections</article-title><source>Clin. Drug Investig.</source><year>1996</year><volume>12</volume><fpage>308</fpage><lpage>317</lpage><pub-id pub-id-type="doi">10.2165/00044011-199612060-00004</pub-id></element-citation></ref><ref id="B79-antibiotics-11-01237"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Duggar</surname><given-names>B.M.</given-names></name>
</person-group><article-title>Aureomycin: A product of the continuing search for new antibiotics</article-title><source>Ann. N. Y. Acad. Sci.</source><year>1948</year><volume>51</volume><fpage>177</fpage><lpage>181</lpage><pub-id pub-id-type="doi">10.1111/j.1749-6632.1948.tb27262.x</pub-id><?supplied-pmid 18112227?><pub-id pub-id-type="pmid">18112227</pub-id></element-citation></ref><ref id="B80-antibiotics-11-01237"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ross</surname><given-names>S.</given-names></name>
<name><surname>Burke</surname><given-names>F.G.</given-names></name>
</person-group><article-title>Aureomycin; preliminary report of a clinical trial</article-title><source>Clin. Proc. Child. Hosp. Dist. Columbia</source><year>1948</year><volume>4</volume><fpage>315</fpage><lpage>331</lpage><pub-id pub-id-type="pmid">18107029</pub-id></element-citation></ref><ref id="B81-antibiotics-11-01237"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chopra</surname><given-names>I.</given-names></name>
<name><surname>Roberts</surname><given-names>M.</given-names></name>
</person-group><article-title>Tetracycline antibiotics: Mode of action, applications, molecular biology, and epidemiology of bacterial resistance</article-title><source>Microbiol. Mol. Biol. Rev.</source><year>2001</year><volume>65</volume><fpage>232</fpage><pub-id pub-id-type="doi">10.1128/MMBR.65.2.232-260.2001</pub-id><pub-id pub-id-type="pmid">11381101</pub-id></element-citation></ref><ref id="B82-antibiotics-11-01237"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hitchings</surname><given-names>G.H.</given-names></name>
<name><surname>Elion</surname><given-names>G.B.</given-names></name>
</person-group><article-title>Pyrimidine derivatives as antagonists of pteroylglutamic acid</article-title><source>J. Biol. Chem.</source><year>1948</year><volume>174</volume><fpage>765</fpage><pub-id pub-id-type="doi">10.1016/S0021-9258(18)57361-0</pub-id><pub-id pub-id-type="pmid">18865647</pub-id></element-citation></ref><ref id="B83-antibiotics-11-01237"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Noall</surname><given-names>E.W.P.</given-names></name>
<name><surname>Sewards</surname><given-names>H.F.G.</given-names></name>
<name><surname>Waterworth</surname><given-names>P.M.</given-names></name>
</person-group><article-title>Successful treatment of a case of <italic toggle="yes">Proteus</italic> septicaemia</article-title><source>Br. Med. J.</source><year>1962</year><volume>2</volume><fpage>1101</fpage><pub-id pub-id-type="doi">10.1136/bmj.2.5312.1101</pub-id><pub-id pub-id-type="pmid">20789534</pub-id></element-citation></ref><ref id="B84-antibiotics-11-01237"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Darrell</surname><given-names>J.H.</given-names></name>
<name><surname>Garrod</surname><given-names>L.P.</given-names></name>
<name><surname>Waterworth</surname><given-names>P.M.</given-names></name>
</person-group><article-title>Trimethoprim: Laboratory and clinical studies</article-title><source>J. Clin. Pathol.</source><year>1968</year><volume>21</volume><fpage>202</fpage><pub-id pub-id-type="doi">10.1136/jcp.21.2.202</pub-id><pub-id pub-id-type="pmid">5697054</pub-id></element-citation></ref><ref id="B85-antibiotics-11-01237"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Finlay</surname><given-names>A.C.</given-names></name>
<name><surname>Hobby</surname><given-names>G.L.</given-names></name>
<name><surname>Hochstein</surname><given-names>F.</given-names></name>
<name><surname>Lees</surname><given-names>T.M.</given-names></name>
<name><surname>Lenert</surname><given-names>T.F.</given-names></name>
<name><surname>Means</surname><given-names>J.A.</given-names></name>
<name><surname>P&#x02019;an</surname><given-names>S.Y.</given-names></name>
<name><surname>Regna</surname><given-names>P.P.</given-names></name>
<name><surname>Routien</surname><given-names>J.B.</given-names></name>
<name><surname>Sobin</surname><given-names>B.A.</given-names></name>
<etal/>
</person-group><article-title>Viomycin, a new antibiotic active against mycobacteria</article-title><source>Am. Rev. Tuberc.</source><year>1951</year><volume>63</volume><fpage>1</fpage><lpage>3</lpage><?supplied-pmid 14799783?><pub-id pub-id-type="pmid">14799783</pub-id></element-citation></ref><ref id="B86-antibiotics-11-01237"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hackney</surname><given-names>R.</given-names></name>
<name><surname>King</surname><given-names>E.</given-names></name>
<name><surname>Marshall</surname><given-names>E.</given-names></name>
<name><surname>Harden</surname><given-names>A.</given-names></name>
<name><surname>Payne</surname><given-names>H.</given-names></name>
</person-group><article-title>Clinical observations on viomycin sulphate in the treatment of tuberculosis</article-title><source>Dis. Chest</source><year>1953</year><volume>24</volume><fpage>591</fpage><lpage>600</lpage><pub-id pub-id-type="doi">10.1378/chest.24.6.591</pub-id><?supplied-pmid 13107556?><pub-id pub-id-type="pmid">13107556</pub-id></element-citation></ref><ref id="B87-antibiotics-11-01237"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tsukamura</surname><given-names>M.</given-names></name>
</person-group><article-title>Drug-resistance test for kanamycin and cross resistance problem in <italic toggle="yes">Mycobacterium tuberculosis</italic> with special reference to kanamycin, streptomycin, and viomycin</article-title><source>J. Antibiot.</source><year>1959</year><volume>12</volume><fpage>189</fpage><lpage>191</lpage></element-citation></ref><ref id="B88-antibiotics-11-01237"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kavanagh</surname><given-names>F.</given-names></name>
<name><surname>Hervey</surname><given-names>A.</given-names></name>
<name><surname>Robbins</surname><given-names>W.J.</given-names></name>
</person-group><article-title>Antibiotic Substances from Basidiomycetes: VIII. Pleurotus Multilus (Fr.) Sacc. and Pleurotus Passeckerianus Pilat</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1951</year><volume>37</volume><fpage>570</fpage><lpage>574</lpage><pub-id pub-id-type="doi">10.1073/pnas.37.9.570</pub-id><pub-id pub-id-type="pmid">16589015</pub-id></element-citation></ref><ref id="B89-antibiotics-11-01237"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Parish</surname><given-names>L.C.</given-names></name>
<name><surname>Jorizzo</surname><given-names>J.L.</given-names></name>
<name><surname>Breton</surname><given-names>J.J.</given-names></name>
<name><surname>Hirman</surname><given-names>J.W.</given-names></name>
<name><surname>Scangarella</surname><given-names>N.E.</given-names></name>
<name><surname>Shawar</surname><given-names>R.M.</given-names></name>
<name><surname>White</surname><given-names>S.M.</given-names></name>
<collab>SB275833/032 Study Team</collab>
</person-group><article-title>Topical retapamulin ointment (1%, wt./wt.) twice daily for 5 days versus oral cephalexin twice daily for 10 days in the treatment of secondarily infected dermatitis: Results of a randomized controlled trial</article-title><source>J. Am. Acad. Dermatol.</source><year>2006</year><volume>55</volume><fpage>1003</fpage><lpage>1013</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2006.08.058</pub-id><?supplied-pmid 17097398?><pub-id pub-id-type="pmid">17097398</pub-id></element-citation></ref><ref id="B90-antibiotics-11-01237"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gentry</surname><given-names>D.R.</given-names></name>
<name><surname>McCloskey</surname><given-names>L.</given-names></name>
<name><surname>Gwynn</surname><given-names>M.N.</given-names></name>
<name><surname>Rittenhouse</surname><given-names>S.F.</given-names></name>
<name><surname>Scangarella</surname><given-names>N.</given-names></name>
<name><surname>Shawar</surname><given-names>R.</given-names></name>
<name><surname>Holmes</surname><given-names>D.J.</given-names></name>
</person-group><article-title>Genetic characterization of VgaABC proteins conferring reduced susceptibility to pleuromutilins in <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>Antimicrob. Agents Chemother.</source><year>2008</year><volume>52</volume><fpage>4507</fpage><lpage>4509</lpage><pub-id pub-id-type="doi">10.1128/AAC.00915-08</pub-id><pub-id pub-id-type="pmid">18838584</pub-id></element-citation></ref><ref id="B91-antibiotics-11-01237"><label>91.</label><element-citation publication-type="journal"><article-title>Erythromycin</article-title><source>Br. Med. J.</source><year>1952</year><volume>2</volume><fpage>1085</fpage><lpage>1086</lpage><pub-id pub-id-type="doi">10.1136/bmj.2.4793.1085</pub-id><pub-id pub-id-type="pmid">12987755</pub-id></element-citation></ref><ref id="B92-antibiotics-11-01237"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Haight</surname><given-names>T.H.</given-names></name>
<name><surname>Finland</surname><given-names>M.</given-names></name>
</person-group><article-title>Laboratory and clinical studies on erythromycin</article-title><source>N. Engl. J. Med.</source><year>1952</year><volume>247</volume><fpage>227</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1056/NEJM195208142470701</pub-id><pub-id pub-id-type="pmid">14947931</pub-id></element-citation></ref><ref id="B93-antibiotics-11-01237"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Haight</surname><given-names>T.H.</given-names></name>
<name><surname>Finland</surname><given-names>M.</given-names></name>
</person-group><article-title>Resistance of bacteria to erythromycin</article-title><source>Exp. Biol. Med.</source><year>1952</year><volume>81</volume><fpage>183</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.3181/00379727-81-19816</pub-id><?supplied-pmid 13047352?><pub-id pub-id-type="pmid">13047352</pub-id></element-citation></ref><ref id="B94-antibiotics-11-01237"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fox</surname><given-names>H.H.</given-names></name>
</person-group><article-title>The chemical attack on tuberculosis</article-title><source>Trans. N. Y. Acad. Sci.</source><year>1953</year><volume>15</volume><fpage>234</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1111/j.2164-0947.1953.tb01314.x</pub-id><pub-id pub-id-type="pmid">13090278</pub-id></element-citation></ref><ref id="B95-antibiotics-11-01237"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bernstein</surname><given-names>J.</given-names></name>
<name><surname>Lott</surname><given-names>W.A.</given-names></name>
<name><surname>Steinberg</surname><given-names>B.A.</given-names></name>
<name><surname>Yale</surname><given-names>H.L.</given-names></name>
</person-group><article-title>Chemotherapy of experimental tuberculosis. V. Isonicotinic acid hydrazide (nydrazid) and related compounds</article-title><source>Am. Rev. Tuberc.</source><year>1952</year><volume>65</volume><fpage>357</fpage><lpage>364</lpage><?supplied-pmid 14903503?><pub-id pub-id-type="pmid">14903503</pub-id></element-citation></ref><ref id="B96-antibiotics-11-01237"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Clark</surname><given-names>C.M.</given-names></name>
<name><surname>Elmendorf</surname><given-names>D.F.</given-names></name>
<name><surname>Cawthon</surname><given-names>W.U.</given-names></name>
<name><surname>Muschenheim</surname><given-names>C.</given-names></name>
<name><surname>McDermott</surname><given-names>W.</given-names></name>
</person-group><article-title>Isoniazid (isonicotinic acid hydrazide) in the treatment of miliary and meningeal tuberculosis</article-title><source>Am. Rev. Tuberc.</source><year>1952</year><volume>66</volume><fpage>391</fpage><lpage>415</lpage><?supplied-pmid 12986175?><pub-id pub-id-type="pmid">12986175</pub-id></element-citation></ref><ref id="B97-antibiotics-11-01237"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nash</surname><given-names>J.C.</given-names></name>
<name><surname>Grosfeld</surname><given-names>W.</given-names></name>
</person-group><article-title>Isoniazid and iproniazid resistance in pulmonary tuberculosis</article-title><source>J. Am. Med. Assoc.</source><year>1952</year><volume>150</volume><fpage>813</fpage></element-citation></ref><ref id="B98-antibiotics-11-01237"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mast</surname><given-names>Y.</given-names></name>
<name><surname>Wohlleben</surname><given-names>W.</given-names></name>
</person-group><article-title>Streptogramins&#x02014;Two are better than one!</article-title><source>Int. J. Med. Microbiol.</source><year>2014</year><volume>304</volume><fpage>44</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1016/j.ijmm.2013.08.008</pub-id><?supplied-pmid 24119565?><pub-id pub-id-type="pmid">24119565</pub-id></element-citation></ref><ref id="B99-antibiotics-11-01237"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jolles</surname><given-names>G.</given-names></name>
<name><surname>Terlain</surname><given-names>B.</given-names></name>
<name><surname>Thomas</surname><given-names>J.P.</given-names></name>
</person-group><article-title>Metabolic investigations on pristinamycin</article-title><source>Nature</source><year>1965</year><volume>207</volume><fpage>199</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.1038/207199a0</pub-id><pub-id pub-id-type="pmid">5886117</pub-id></element-citation></ref><ref id="B100-antibiotics-11-01237"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dublanchet</surname><given-names>A.</given-names></name>
<name><surname>Soussy</surname><given-names>C.J.</given-names></name>
<name><surname>Squinazi</surname><given-names>F.</given-names></name>
<name><surname>Duval</surname><given-names>J.</given-names></name>
</person-group><article-title>Resistance to streptogramin antibiotics in <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>Ann. Microbiol.</source><year>1977</year><volume>128A</volume><fpage>277</fpage><lpage>287</lpage></element-citation></ref><ref id="B101-antibiotics-11-01237"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rist</surname><given-names>N.</given-names></name>
<name><surname>Grumbach</surname><given-names>F.</given-names></name>
<name><surname>Libermann</surname><given-names>D.</given-names></name>
</person-group><article-title>Experiments on the antituberculous activity of alpha-ethylthioisonicotinamide</article-title><source>Am. Rev. Tuberc.</source><year>1959</year><volume>79</volume><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">13606329</pub-id></element-citation></ref><ref id="B102-antibiotics-11-01237"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Robson</surname><given-names>J.M.</given-names></name>
<name><surname>Sullivan</surname><given-names>F.M.</given-names></name>
</person-group><article-title>Antituberculosis drugs</article-title><source>Pharmacol. Rev.</source><year>1963</year><volume>15</volume><fpage>169</fpage><lpage>223</lpage><pub-id pub-id-type="pmid">13974496</pub-id></element-citation></ref><ref id="B103-antibiotics-11-01237"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fairbrother</surname><given-names>R.W.</given-names></name>
<name><surname>Williams</surname><given-names>B.L.</given-names></name>
</person-group><article-title>Two new antibiotics: Antibacterial activity of novobiocin and vancomycin</article-title><source>Lancet</source><year>1956</year><volume>268</volume><fpage>1177</fpage><lpage>1179</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(56)90052-6</pub-id></element-citation></ref><ref id="B104-antibiotics-11-01237"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Geraci</surname><given-names>J.E.</given-names></name>
<name><surname>Heilman</surname><given-names>F.R.</given-names></name>
<name><surname>Nichols</surname><given-names>D.R.</given-names></name>
<name><surname>Wellman</surname><given-names>W.E.</given-names></name>
</person-group><article-title>Antibiotic therapy of bacterial endocarditis. VII. Vancomycin for acute micrococcal endocarditis; preliminary report</article-title><source>Proc. Staff Meet. Mayo Clin.</source><year>1958</year><volume>33</volume><fpage>172</fpage><lpage>181</lpage><pub-id pub-id-type="pmid">13542649</pub-id></element-citation></ref><ref id="B105-antibiotics-11-01237"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Courvalin</surname><given-names>P.</given-names></name>
</person-group><article-title>Vancomycin resistance in Gram-positive cocci</article-title><source>Clin. Infect. Dis.</source><year>2006</year><volume>42</volume><fpage>S25</fpage><lpage>S34</lpage><pub-id pub-id-type="doi">10.1086/491711</pub-id><?supplied-pmid 16323116?><pub-id pub-id-type="pmid">16323116</pub-id></element-citation></ref><ref id="B106-antibiotics-11-01237"><label>106.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>De Boer</surname><given-names>C.</given-names></name>
<name><surname>Dietz</surname><given-names>A.</given-names></name>
<name><surname>Wilkins</surname><given-names>J.R.</given-names></name>
<name><surname>Lewis</surname><given-names>C.N.</given-names></name>
<name><surname>Savage</surname><given-names>G.M.</given-names></name>
</person-group><article-title>Celesticetin&#x02014;A new, crystalline antibiotic. I. Biologic studies of celesticetin</article-title><source>Antibiotics Annual</source><edition>6th ed.</edition><person-group person-group-type="editor">
<name><surname>Welch</surname><given-names>H.</given-names></name>
<name><surname>Marti-Ibanez</surname><given-names>F.</given-names></name>
</person-group><publisher-name>Interscience Publishers</publisher-name><publisher-loc>Chichester, UK</publisher-loc><year>1955</year><fpage>831</fpage><lpage>836</lpage></element-citation></ref><ref id="B107-antibiotics-11-01237"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schaffer</surname><given-names>L.</given-names></name>
<name><surname>Finkelstein</surname><given-names>J.</given-names></name>
<name><surname>Hohn</surname><given-names>A.</given-names></name>
<name><surname>Lees</surname><given-names>T.M.</given-names></name>
<name><surname>Lenert</surname><given-names>T.F.</given-names></name>
<name><surname>Means</surname><given-names>J.A.</given-names></name>
<name><surname>P&#x02019;an</surname><given-names>S.Y.</given-names></name>
<name><surname>Regna</surname><given-names>P.P.</given-names></name>
<name><surname>Routien</surname><given-names>J.B.</given-names></name>
<name><surname>Sobin</surname><given-names>B.A.</given-names></name>
<etal/>
</person-group><article-title>Lincomycin&#x02014;A new antibiotic: Studies in children carrying &#x003b2;-hemolytic streptococci in association with acute pharyngitis, tonsillitis, or both</article-title><source>Clin. Pediatrics</source><year>1963</year><volume>2</volume><fpage>642</fpage><lpage>645</lpage><pub-id pub-id-type="doi">10.1177/000992286300201110</pub-id><?supplied-pmid 14079244?><pub-id pub-id-type="pmid">14079244</pub-id></element-citation></ref><ref id="B108-antibiotics-11-01237"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Desmyter</surname><given-names>J.</given-names></name>
</person-group><article-title>Lincomycin resistance of erythromycin-resistant cocci</article-title><source>N. Engl. J. Med.</source><year>1968</year><volume>278</volume><fpage>967</fpage></element-citation></ref><ref id="B109-antibiotics-11-01237"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Epstein</surname><given-names>I.G.</given-names></name>
<name><surname>Nair</surname><given-names>K.G.</given-names></name>
<name><surname>Boyd</surname><given-names>L.J.</given-names></name>
</person-group><article-title>Cycloserine, a new antibiotic, in the treatment of human pulmonary tuberculosis: A preliminary report</article-title><source>Antibiot. Med. Clin. Ther.</source><year>1955</year><volume>1</volume><fpage>80</fpage><lpage>93</lpage></element-citation></ref><ref id="B110-antibiotics-11-01237"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Epstein</surname><given-names>I.G.</given-names></name>
<name><surname>Nair</surname><given-names>K.G.</given-names></name>
<name><surname>Boyd</surname><given-names>L.J.</given-names></name>
</person-group><article-title>The treatment of human pulmonary tuberculosis with cycloserine: Progress report</article-title><source>Dis. Chest</source><year>1956</year><volume>29</volume><fpage>241</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.1378/chest.29.3.241</pub-id><pub-id pub-id-type="pmid">13294011</pub-id></element-citation></ref><ref id="B111-antibiotics-11-01237"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Storey</surname><given-names>P.B.</given-names></name>
<name><surname>Mclean</surname><given-names>R.L.</given-names></name>
</person-group><article-title>A current appraisal of cycloserine</article-title><source>Antibiot. Med. Clin. Ther.</source><year>1957</year><volume>4</volume><fpage>223</fpage><lpage>232</lpage></element-citation></ref><ref id="B112-antibiotics-11-01237"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sensi</surname><given-names>P.</given-names></name>
</person-group><article-title>History of the development of rifampin</article-title><source>Rev. Infect. Dis.</source><year>1983</year><volume>5</volume><fpage>S402</fpage><lpage>S406</lpage><pub-id pub-id-type="doi">10.1093/clinids/5.Supplement_3.S402</pub-id><pub-id pub-id-type="pmid">6635432</pub-id></element-citation></ref><ref id="B113-antibiotics-11-01237"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kontomichalou</surname><given-names>P.</given-names></name>
<name><surname>Papadakis</surname><given-names>Z.</given-names></name>
<name><surname>Daikos</surname><given-names>G.</given-names></name>
</person-group><article-title>Rifamycin SV: Clinical and laboratory experience</article-title><source>Chemotherapy</source><year>1963</year><volume>7</volume><fpage>357</fpage><lpage>364</lpage><pub-id pub-id-type="doi">10.1159/000220144</pub-id></element-citation></ref><ref id="B114-antibiotics-11-01237"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Manten</surname><given-names>A.</given-names></name>
<name><surname>van Wijngaarden</surname><given-names>L.J.</given-names></name>
</person-group><article-title>Development of drug resistance to rifampicin</article-title><source>Chemotherapy</source><year>1969</year><volume>14</volume><fpage>93</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1159/000220615</pub-id><?supplied-pmid 4979978?><pub-id pub-id-type="pmid">4979978</pub-id></element-citation></ref><ref id="B115-antibiotics-11-01237"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Van Dijck</surname><given-names>P.J.</given-names></name>
<name><surname>De Somer</surname><given-names>P.</given-names></name>
</person-group><article-title>Ramycin: A new antibiotic</article-title><source>J. Gen. Microbiol.</source><year>1958</year><volume>18</volume><fpage>377</fpage><lpage>381</lpage><pub-id pub-id-type="doi">10.1099/00221287-18-2-377</pub-id><pub-id pub-id-type="pmid">13525656</pub-id></element-citation></ref><ref id="B116-antibiotics-11-01237"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Godtfredsen</surname><given-names>W.O.</given-names></name>
<name><surname>Jahnsen</surname><given-names>S.</given-names></name>
<name><surname>Lorck</surname><given-names>H.</given-names></name>
<name><surname>Roholt</surname><given-names>K.</given-names></name>
<name><surname>Tybring</surname><given-names>L.</given-names></name>
</person-group><article-title>Fusidic acid: A new antibiotic</article-title><source>Nature</source><year>1962</year><volume>193</volume><fpage>987</fpage><pub-id pub-id-type="doi">10.1038/193987a0</pub-id><?supplied-pmid 13899435?><pub-id pub-id-type="pmid">13899435</pub-id></element-citation></ref><ref id="B117-antibiotics-11-01237"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vanderhaeghe</surname><given-names>H.</given-names></name>
<name><surname>van Dijck</surname><given-names>P.</given-names></name>
<name><surname>De Somer</surname><given-names>P.</given-names></name>
</person-group><article-title>Identity of ramycin with fusidic acid</article-title><source>Nature</source><year>1965</year><volume>205</volume><fpage>710</fpage><lpage>711</lpage><pub-id pub-id-type="doi">10.1038/205710a0</pub-id><?supplied-pmid 14287421?><pub-id pub-id-type="pmid">14287421</pub-id></element-citation></ref><ref id="B118-antibiotics-11-01237"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Newman</surname><given-names>R.L.</given-names></name>
<name><surname>Bhat</surname><given-names>K.M.</given-names></name>
<name><surname>Hackney</surname><given-names>R.</given-names></name>
<name><surname>Robinson</surname><given-names>C.</given-names></name>
<name><surname>Stewart</surname><given-names>G.T.</given-names></name>
</person-group><article-title>Fusidic acid: Laboratory and clinical assessment</article-title><source>Br. Med. J.</source><year>1962</year><volume>2</volume><fpage>1645</fpage><pub-id pub-id-type="doi">10.1136/bmj.2.5320.1645</pub-id><?supplied-pmid 13938269?><pub-id pub-id-type="pmid">13938269</pub-id></element-citation></ref><ref id="B119-antibiotics-11-01237"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Evans</surname><given-names>R.J.</given-names></name>
<name><surname>Waterworth</surname><given-names>P.M.</given-names></name>
</person-group><article-title>Naturally-occurring fusidic acid resistance in staphylococci and its linkage to other resistances</article-title><source>J. Clin. Pathol.</source><year>1966</year><volume>19</volume><fpage>555</fpage><pub-id pub-id-type="doi">10.1136/jcp.19.6.555</pub-id><?supplied-pmid 5928604?><pub-id pub-id-type="pmid">5928604</pub-id></element-citation></ref><ref id="B120-antibiotics-11-01237"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cosar</surname><given-names>C.</given-names></name>
<name><surname>Julou</surname><given-names>L.</given-names></name>
</person-group><article-title>The activity of 1-(2-hydroxyethyl)-2-methyl-5-nitroimidazole (R. P. 8823) against experimental <italic toggle="yes">Trichomonas vaginalis</italic> infections</article-title><source>Ann. Inst. Pasteur</source><year>1959</year><volume>96</volume><fpage>238</fpage><lpage>241</lpage><pub-id pub-id-type="pmid">13627590</pub-id></element-citation></ref><ref id="B121-antibiotics-11-01237"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shinn</surname><given-names>D.L.S.</given-names></name>
</person-group><article-title>Metronidazole in acute ulcerative gingivitis</article-title><source>Lancet</source><year>1962</year><volume>279</volume><fpage>1191</fpage><pub-id pub-id-type="doi">10.1016/S0140-6736(62)92243-2</pub-id></element-citation></ref><ref id="B122-antibiotics-11-01237"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ingham</surname><given-names>H.R.</given-names></name>
<name><surname>Eaton</surname><given-names>S.</given-names></name>
<name><surname>Venables</surname><given-names>C.W.</given-names></name>
<name><surname>Adams</surname><given-names>P.C.</given-names></name>
</person-group><article-title><italic toggle="yes">Bacteroides fragilis</italic> resistant to metronidazole after long-term therapy</article-title><source>Lancet</source><year>1978</year><volume>1</volume><fpage>214</fpage><pub-id pub-id-type="doi">10.1016/S0140-6736(78)90655-4</pub-id></element-citation></ref><ref id="B123-antibiotics-11-01237"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thomas</surname><given-names>J.P.</given-names></name>
<name><surname>Baughn</surname><given-names>C.O.</given-names></name>
<name><surname>Wilkinson</surname><given-names>R.G.</given-names></name>
<name><surname>Shepherd</surname><given-names>R.G.</given-names></name>
</person-group><article-title>A new synthetic compound with antituberculous activity in mice: Ethambutol (dextro-2,2&#x02032;-(ethylenediimino)-di-l-butanol)</article-title><source>Am. Rev. Respir. Dis.</source><year>1961</year><volume>83</volume><fpage>891</fpage><lpage>893</lpage><pub-id pub-id-type="pmid">13776497</pub-id></element-citation></ref><ref id="B124-antibiotics-11-01237"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Carr</surname><given-names>R.E.</given-names></name>
<name><surname>Henkind</surname><given-names>P.</given-names></name>
</person-group><article-title>Ocular manifestations of ethambutol, toxic amblyopia after administration of an experimental antituberculous drug</article-title><source>Arch. Ophthalmol.</source><year>1962</year><volume>67</volume><fpage>566</fpage><lpage>571</lpage><pub-id pub-id-type="doi">10.1001/archopht.1962.00960020566009</pub-id><pub-id pub-id-type="pmid">13876814</pub-id></element-citation></ref><ref id="B125-antibiotics-11-01237"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hobby</surname><given-names>G.L.</given-names></name>
<name><surname>Johnson</surname><given-names>P.M.</given-names></name>
<name><surname>Boytar-Papirnyik</surname><given-names>V.</given-names></name>
<name><surname>Wilber</surname><given-names>J.</given-names></name>
</person-group><article-title>Primary drug resistance: A continuing study of tubercle bacilli in a veteran population within the United States. VI. Initial observations on the incidence of resistance to rifampin and ethambutol</article-title><source>Am. Rev. Respir. Dis.</source><year>1969</year><volume>99</volume><fpage>777</fpage><lpage>779</lpage><pub-id pub-id-type="pmid">4978401</pub-id></element-citation></ref><ref id="B126-antibiotics-11-01237"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lesher</surname><given-names>G.Y.</given-names></name>
<name><surname>Froelich</surname><given-names>E.J.</given-names></name>
<name><surname>Gruett</surname><given-names>M.D.</given-names></name>
<name><surname>Bailey</surname><given-names>J.H.</given-names></name>
<name><surname>Brundage</surname><given-names>R.P.</given-names></name>
</person-group><article-title>1,8-naphthyridine derivatives. A new class of chemotherapeutic agents</article-title><source>J. Med. Pharm. Chem.</source><year>1962</year><volume>91</volume><fpage>1063</fpage><lpage>1065</lpage><pub-id pub-id-type="doi">10.1021/jm01240a021</pub-id><?supplied-pmid 14056431?><pub-id pub-id-type="pmid">14056431</pub-id></element-citation></ref><ref id="B127-antibiotics-11-01237"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Barlow</surname><given-names>A.M.</given-names></name>
</person-group><article-title>Nalidixic acid in infections of urinary tract</article-title><source>Br. Med. J.</source><year>1963</year><volume>2</volume><fpage>1308</fpage><pub-id pub-id-type="doi">10.1136/bmj.2.5368.1308</pub-id><?supplied-pmid 14058206?><pub-id pub-id-type="pmid">14058206</pub-id></element-citation></ref><ref id="B128-antibiotics-11-01237"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ronald</surname><given-names>A.R.</given-names></name>
<name><surname>Turck</surname><given-names>M.</given-names></name>
<name><surname>Petersdorf</surname><given-names>R.G.</given-names></name>
</person-group><article-title>A critical evaluation of nalidixic acid in urinary-tract infections</article-title><source>N. Engl. J. Med.</source><year>1966</year><volume>275</volume><fpage>1081</fpage><lpage>1089</lpage><pub-id pub-id-type="doi">10.1056/NEJM196611172752001</pub-id><pub-id pub-id-type="pmid">5923022</pub-id></element-citation></ref><ref id="B129-antibiotics-11-01237"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hendlin</surname><given-names>D.</given-names></name>
<name><surname>Stapley</surname><given-names>E.O.</given-names></name>
<name><surname>Jackson</surname><given-names>M.</given-names></name>
<name><surname>Wallick</surname><given-names>H.</given-names></name>
<name><surname>Miller</surname><given-names>A.K.</given-names></name>
<name><surname>Wolf</surname><given-names>F.J.</given-names></name>
<name><surname>Miller</surname><given-names>T.W.</given-names></name>
<name><surname>Chaiet</surname><given-names>L.</given-names></name>
<name><surname>Kahan</surname><given-names>F.M.</given-names></name>
<name><surname>Foltz</surname><given-names>E.L.</given-names></name>
<etal/>
</person-group><article-title>Phosphonomycin, a new antibiotic produced by strains of streptomyces</article-title><source>Science</source><year>1969</year><volume>166</volume><fpage>122</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1126/science.166.3901.122</pub-id><?supplied-pmid 5809587?><pub-id pub-id-type="pmid">5809587</pub-id></element-citation></ref><ref id="B130-antibiotics-11-01237"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lagunero</surname><given-names>R.L.</given-names></name>
<name><surname>Men&#x000e9;ndez</surname><given-names>M.L.</given-names></name>
</person-group><article-title>Urinary tract infections treated with phosphonomycin (author&#x02019;s translation)</article-title><source>Folia Clin. Int.</source><year>1974</year><volume>24</volume><fpage>130</fpage><lpage>148</lpage></element-citation></ref><ref id="B131-antibiotics-11-01237"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Courtieu</surname><given-names>A.L.</given-names></name>
<name><surname>Drugeon</surname><given-names>H.</given-names></name>
<name><surname>Billaudel</surname><given-names>S.</given-names></name>
</person-group><article-title>Susceptibility to fosfomycin of hospital strains isolated in Nantes (France). Frequency of mutation to resistance</article-title><source>Chemotherapy</source><year>1977</year><volume>23</volume><fpage>25</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1159/000222023</pub-id></element-citation></ref><ref id="B132-antibiotics-11-01237"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fuller</surname><given-names>A.T.</given-names></name>
<name><surname>Mellows</surname><given-names>G.</given-names></name>
<name><surname>Woolford</surname><given-names>M.</given-names></name>
<name><surname>Banks</surname><given-names>G.T.</given-names></name>
<name><surname>Barrow</surname><given-names>K.D.</given-names></name>
<name><surname>Chain</surname><given-names>E.B.</given-names></name>
</person-group><article-title>Pseudomonic acid: An antibiotic produced by <italic toggle="yes">Pseudomonas fluorescens</italic></article-title><source>Nature</source><year>1971</year><volume>234</volume><fpage>416</fpage><lpage>417</lpage><pub-id pub-id-type="doi">10.1038/234416a0</pub-id><?supplied-pmid 5003547?><pub-id pub-id-type="pmid">5003547</pub-id></element-citation></ref><ref id="B133-antibiotics-11-01237"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lever</surname><given-names>L.R.</given-names></name>
<name><surname>Leigh</surname><given-names>D.A.</given-names></name>
<name><surname>Wilkinson</surname><given-names>J.D.</given-names></name>
</person-group><article-title>A double-blind study to assess the effectiveness of mupirocin in the treatment of infected eczema</article-title><source>Br. J. Dermatol.</source><year>1985</year><volume>113</volume><fpage>35</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2133.1985.tb12999.x</pub-id></element-citation></ref><ref id="B134-antibiotics-11-01237"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rahman</surname><given-names>M.</given-names></name>
<name><surname>Noble</surname><given-names>W.C.</given-names></name>
<name><surname>Cookson</surname><given-names>B.</given-names></name>
<name><surname>Baird</surname><given-names>D.</given-names></name>
<name><surname>Coia</surname><given-names>J.</given-names></name>
</person-group><article-title>Mupirocin-resistant <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>Lancet</source><year>1987</year><volume>330</volume><fpage>387</fpage><lpage>388</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(87)92398-1</pub-id></element-citation></ref><ref id="B135-antibiotics-11-01237"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Coronelli</surname><given-names>C.</given-names></name>
<name><surname>White</surname><given-names>R.J.</given-names></name>
<name><surname>Lancini</surname><given-names>G.C.</given-names></name>
<name><surname>Parenti</surname><given-names>F.</given-names></name>
</person-group><article-title>Lipiarmycin, a new antibiotic from <italic toggle="yes">Actinoplanes</italic>. II. Isolation, chemical, biological and biochemical characterization</article-title><source>J. Antibiot.</source><year>1975</year><volume>28</volume><fpage>253</fpage><lpage>259</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.28.253</pub-id></element-citation></ref><ref id="B136-antibiotics-11-01237"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Citron</surname><given-names>D.M.</given-names></name>
<name><surname>Babakhani</surname><given-names>F.</given-names></name>
<name><surname>Goldstein</surname><given-names>E.J.C.</given-names></name>
<name><surname>Nagaro</surname><given-names>K.</given-names></name>
<name><surname>Sambol</surname><given-names>S.</given-names></name>
<name><surname>Sears</surname><given-names>P.</given-names></name>
<name><surname>Shue</surname><given-names>Y.-K.</given-names></name>
<name><surname>Gerding</surname><given-names>D.N.</given-names></name>
</person-group><article-title>Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for <italic toggle="yes">C. difficile</italic> infection</article-title><source>Anaerobe</source><year>2009</year><volume>15</volume><fpage>234</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1016/j.anaerobe.2009.09.005</pub-id><?supplied-pmid 19755166?><pub-id pub-id-type="pmid">19755166</pub-id></element-citation></ref><ref id="B137-antibiotics-11-01237"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schwanbeck</surname><given-names>J.</given-names></name>
<name><surname>Riedel</surname><given-names>T.</given-names></name>
<name><surname>Laukien</surname><given-names>F.</given-names></name>
<name><surname>Schober</surname><given-names>I.</given-names></name>
<name><surname>Oehmig</surname><given-names>I.</given-names></name>
<name><surname>Zimmermann</surname><given-names>O.</given-names></name>
<name><surname>Overmann</surname><given-names>J.</given-names></name>
<name><surname>Gro&#x000df;</surname><given-names>U.</given-names></name>
<name><surname>Zautner</surname><given-names>A.E.</given-names></name>
<name><surname>Bohne</surname><given-names>W.</given-names></name>
</person-group><article-title>Characterization of a clinical <italic toggle="yes">Clostridioides difficile</italic> isolate with markedly reduced fidaxomicin susceptibility and a V1143D mutation in <italic toggle="yes">rpoB</italic></article-title><source>J. Antimicrob. Chemother.</source><year>2019</year><volume>74</volume><fpage>6</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1093/jac/dky375</pub-id><?supplied-pmid 30247587?><pub-id pub-id-type="pmid">30247587</pub-id></element-citation></ref><ref id="B138-antibiotics-11-01237"><label>138.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Baker</surname><given-names>F.</given-names></name>
<name><surname>Cama</surname><given-names>L.D.</given-names></name>
<name><surname>Christensen</surname><given-names>B.G.</given-names></name>
<name><surname>Leanza</surname><given-names>W.J.</given-names></name>
<name><surname>Shih</surname><given-names>D.H.</given-names></name>
<name><surname>Wildonger</surname><given-names>K.J.</given-names></name>
</person-group><article-title>Thienamycin, imipenem and new members of the carbapenem class of &#x003b2;-lactam antibiotics</article-title><source>IUPHAR 9th International Congress of Pharmacology London 1984</source><person-group person-group-type="editor">
<name><surname>Paton</surname><given-names>W.</given-names></name>
<name><surname>Mitchell</surname><given-names>J.</given-names></name>
<name><surname>Turner</surname><given-names>P.</given-names></name>
</person-group><publisher-name>Palgrave Macmillan</publisher-name><publisher-loc>London, UK</publisher-loc><year>1984</year><fpage>105</fpage><lpage>109</lpage></element-citation></ref><ref id="B139-antibiotics-11-01237"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Eron</surname><given-names>L.J.</given-names></name>
<name><surname>Hixon</surname><given-names>D.L.</given-names></name>
<name><surname>Park</surname><given-names>C.H.</given-names></name>
<name><surname>Goldenberg</surname><given-names>R.I.</given-names></name>
<name><surname>Poretz</surname><given-names>D.M.</given-names></name>
</person-group><article-title>Imipenem versus moxalactam in the treatment of serious infections</article-title><source>Antimicrob. Agents Chemother.</source><year>1983</year><volume>24</volume><fpage>841</fpage><pub-id pub-id-type="doi">10.1128/AAC.24.6.841</pub-id><pub-id pub-id-type="pmid">6581755</pub-id></element-citation></ref><ref id="B140-antibiotics-11-01237"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Quinn</surname><given-names>J.P.</given-names></name>
<name><surname>Dudek</surname><given-names>E.J.</given-names></name>
<name><surname>DiVincenzo</surname><given-names>C.A.</given-names></name>
<name><surname>Lucks</surname><given-names>D.A.</given-names></name>
<name><surname>Lerner</surname><given-names>S.A.</given-names></name>
</person-group><article-title>Emergence of resistance to imipenem during therapy for <italic toggle="yes">Pseudomonas aeruginosa</italic> infections</article-title><source>J. Infect. Dis.</source><year>1986</year><volume>154</volume><fpage>289</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1093/infdis/154.2.289</pub-id><pub-id pub-id-type="pmid">3088133</pub-id></element-citation></ref><ref id="B141-antibiotics-11-01237"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Percival</surname><given-names>A.</given-names></name>
<name><surname>Thomas</surname><given-names>E.</given-names></name>
<name><surname>Hart</surname><given-names>C.A.</given-names></name>
<name><surname>Karayiannis</surname><given-names>P.</given-names></name>
</person-group><article-title><italic toggle="yes">In-vitro</italic> activity of monobactam, SQ 26,776, against Gram-negative bacteria</article-title><source>J. Antimicrob. Chemother.</source><year>1981</year><volume>8</volume><fpage>49</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1093/jac/8.suppl_E.49</pub-id></element-citation></ref><ref id="B142-antibiotics-11-01237"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Giamarellou</surname><given-names>H.</given-names></name>
<name><surname>Galanakis</surname><given-names>N.</given-names></name>
<name><surname>Douzinas</surname><given-names>E.</given-names></name>
<name><surname>Petrikkos</surname><given-names>G.</given-names></name>
<name><surname>El Messidi</surname><given-names>M.</given-names></name>
<name><surname>Papoulias</surname><given-names>G.</given-names></name>
<name><surname>Daikos</surname><given-names>G.K.</given-names></name>
</person-group><article-title>Evaluation of aztreonam in difficult-to-treat infections with prolonged posttreatment follow-up</article-title><source>Antimicrob. Agents Chemother.</source><year>1984</year><volume>26</volume><fpage>245</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.1128/AAC.26.2.245</pub-id><?supplied-pmid 6541453?><pub-id pub-id-type="pmid">6541453</pub-id></element-citation></ref><ref id="B143-antibiotics-11-01237"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dworzack</surname><given-names>D.L.</given-names></name>
<name><surname>Bartelt</surname><given-names>M.A.</given-names></name>
<name><surname>Bailey</surname><given-names>R.T.</given-names></name>
<name><surname>Fitzgibbons</surname><given-names>R.J.</given-names></name>
<name><surname>Reich</surname><given-names>J.W.</given-names></name>
<name><surname>Picetti</surname><given-names>G.D.</given-names></name>
</person-group><article-title>Emergence of resistance to aztreonam</article-title><source>Clin. Pharm.</source><year>1984</year><volume>3</volume><fpage>467</fpage><lpage>470</lpage><pub-id pub-id-type="pmid">6541543</pub-id></element-citation></ref><ref id="B144-antibiotics-11-01237"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Slee</surname><given-names>A.M.</given-names></name>
<name><surname>Wuonola</surname><given-names>M.A.</given-names></name>
<name><surname>McRipley</surname><given-names>R.J.</given-names></name>
<name><surname>Zajac</surname><given-names>I.</given-names></name>
<name><surname>Zawada</surname><given-names>M.J.</given-names></name>
<name><surname>Bartholomew</surname><given-names>P.T.</given-names></name>
<name><surname>Gregory</surname><given-names>W.A.</given-names></name>
<name><surname>Forbes</surname><given-names>M.</given-names></name>
</person-group><article-title>Oxazolidinones, a new class of synthetic antibacterial agents: In vitro and in vivo activities of DuP 105 and DuP 721</article-title><source>Antimicrob. Agents Chemother.</source><year>1987</year><volume>31</volume><fpage>1791</fpage><lpage>1797</lpage><pub-id pub-id-type="doi">10.1128/AAC.31.11.1791</pub-id><pub-id pub-id-type="pmid">3435127</pub-id></element-citation></ref><ref id="B145-antibiotics-11-01237"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Riedl</surname><given-names>B.</given-names></name>
<name><surname>Endermann</surname><given-names>R.</given-names></name>
</person-group><article-title>Recent developments with oxazolidinone antibiotics</article-title><source>Expert Opin. Ther. Pat.</source><year>1999</year><volume>9</volume><fpage>625</fpage><lpage>633</lpage><pub-id pub-id-type="doi">10.1517/13543776.9.5.625</pub-id></element-citation></ref><ref id="B146-antibiotics-11-01237"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tsiodras</surname><given-names>S.</given-names></name>
<name><surname>Gold</surname><given-names>H.S.</given-names></name>
<name><surname>Sakoulas</surname><given-names>G.</given-names></name>
<name><surname>Eliopoulos</surname><given-names>G.M.</given-names></name>
<name><surname>Wennersten</surname><given-names>C.</given-names></name>
<name><surname>Venkataraman</surname><given-names>L.</given-names></name>
<name><surname>Moellering</surname><given-names>R.C.</given-names></name>
<name><surname>Ferraro</surname><given-names>M.J.</given-names></name>
</person-group><article-title>Linezolid resistance in a clinical isolate of <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>Lancet</source><year>2001</year><volume>358</volume><fpage>207</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(01)05410-1</pub-id><pub-id pub-id-type="pmid">11476839</pub-id></element-citation></ref><ref id="B147-antibiotics-11-01237"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ehlert</surname><given-names>F.</given-names></name>
<name><surname>Neu</surname><given-names>H.C.</given-names></name>
</person-group><article-title><italic toggle="yes">In vitro</italic> activity of LY146032 (daptomycin), a new peptolide</article-title><source>Eur. J. Clin. Microbiol.</source><year>1987</year><volume>6</volume><fpage>84</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1007/BF02097208</pub-id><?supplied-pmid 3032611?><pub-id pub-id-type="pmid">3032611</pub-id></element-citation></ref><ref id="B148-antibiotics-11-01237"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tally</surname><given-names>F.P.</given-names></name>
<name><surname>Zeckel</surname><given-names>M.</given-names></name>
<name><surname>Wasilewski</surname><given-names>M.M.</given-names></name>
<name><surname>Carini</surname><given-names>C.</given-names></name>
<name><surname>Berman</surname><given-names>C.L.</given-names></name>
<name><surname>Drusano</surname><given-names>G.L.</given-names></name>
<name><surname>Oleson</surname><given-names>F.B.</given-names></name>
</person-group><article-title>Daptomycin: A novel agent for Gram-positive infections</article-title><source>Expert Opin. Investig. Drugs</source><year>1999</year><volume>8</volume><fpage>1223</fpage><lpage>1238</lpage><pub-id pub-id-type="doi">10.1517/13543784.8.8.1223</pub-id></element-citation></ref><ref id="B149-antibiotics-11-01237"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lewis</surname><given-names>J.S.</given-names></name>
<name><surname>Owens</surname><given-names>A.</given-names></name>
<name><surname>Cadena</surname><given-names>J.</given-names></name>
<name><surname>Sabol</surname><given-names>K.</given-names></name>
<name><surname>Patterson</surname><given-names>J.E.</given-names></name>
<name><surname>Jorgensen</surname><given-names>J.H.</given-names></name>
</person-group><article-title>Emergence of daptomycin resistance in <italic toggle="yes">Enterococcus faecium</italic> during daptomycin therapy</article-title><source>Antimicrob. Agents Chemother.</source><year>2005</year><volume>49</volume><fpage>1664</fpage><lpage>1665</lpage><pub-id pub-id-type="pmid">15793168</pub-id></element-citation></ref><ref id="B150-antibiotics-11-01237"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Andries</surname><given-names>K.</given-names></name>
<name><surname>Verhasselt</surname><given-names>P.</given-names></name>
<name><surname>Guillemont</surname><given-names>J.</given-names></name>
<name><surname>G&#x000f6;hlmann</surname><given-names>H.W.H.</given-names></name>
<name><surname>Neefs</surname><given-names>J.-M.</given-names></name>
<name><surname>Winkler</surname><given-names>H.</given-names></name>
<name><surname>van Gestel</surname><given-names>F.</given-names></name>
<name><surname>Timmerman</surname><given-names>P.</given-names></name>
<name><surname>Zhu</surname><given-names>M.</given-names></name>
<name><surname>Lee</surname><given-names>E.</given-names></name>
<etal/>
</person-group><article-title>A diarylquinoline drug active on the ATP synthase of <italic toggle="yes">Mycobacterium tuberculosis</italic></article-title><source>Science</source><year>2005</year><volume>307</volume><fpage>223</fpage><lpage>227</lpage><pub-id pub-id-type="doi">10.1126/science.1106753</pub-id><?supplied-pmid 15591164?><pub-id pub-id-type="pmid">15591164</pub-id></element-citation></ref><ref id="B151-antibiotics-11-01237"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rustomjee</surname><given-names>R.</given-names></name>
<name><surname>Diacon</surname><given-names>A.H.</given-names></name>
<name><surname>Allen</surname><given-names>J.</given-names></name>
<name><surname>Venter</surname><given-names>A.</given-names></name>
<name><surname>Reddy</surname><given-names>C.</given-names></name>
<name><surname>Patientia</surname><given-names>R.F.</given-names></name>
<name><surname>Mthiyane</surname><given-names>T.C.P.</given-names></name>
<name><surname>de Marez</surname><given-names>T.</given-names></name>
<name><surname>van Heeswijk</surname><given-names>R.</given-names></name>
<name><surname>Kerstens</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis</article-title><source>Antimicrob. Agents Chemother.</source><year>2008</year><volume>52</volume><fpage>2831</fpage><pub-id pub-id-type="doi">10.1128/AAC.01204-07</pub-id><?supplied-pmid 18505852?><pub-id pub-id-type="pmid">18505852</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="antibiotics-11-01237-f002"><label>Figure 2</label><caption><p>The cumulative discovery of the 38 classes of clinically used antibiotics. The Golden Age of discovery is highlighted in yellow.</p></caption><graphic xlink:href="antibiotics-11-01237-g002" position="float"/></fig><table-wrap position="float" id="antibiotics-11-01237-t001"><object-id pub-id-type="pii">antibiotics-11-01237-t001_Table 1</object-id><label>Table 1</label><caption><p>The data used to generate <xref rid="antibiotics-11-01237-f001" ref-type="fig">Figure 1</xref> and <xref rid="antibiotics-11-01237-f002" ref-type="fig">Figure 2</xref>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Antibiotic Class</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Discovery Date</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Clinical Use Date</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Resistance Date</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Organoarsenics</td><td align="center" valign="middle" rowspan="1" colspan="1">1909 [<xref rid="B42-antibiotics-11-01237" ref-type="bibr">42</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1910 [<xref rid="B42-antibiotics-11-01237" ref-type="bibr">42</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1912 [<xref rid="B43-antibiotics-11-01237" ref-type="bibr">43</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Penicillins</td><td align="center" valign="middle" rowspan="1" colspan="1">1928 [<xref rid="B44-antibiotics-11-01237" ref-type="bibr">44</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1941 [<xref rid="B45-antibiotics-11-01237" ref-type="bibr">45</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1945 [<xref rid="B46-antibiotics-11-01237" ref-type="bibr">46</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Sulfonamides</td><td align="center" valign="middle" rowspan="1" colspan="1">1932 [<xref rid="B42-antibiotics-11-01237" ref-type="bibr">42</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1935 [<xref rid="B47-antibiotics-11-01237" ref-type="bibr">47</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1939 [<xref rid="B48-antibiotics-11-01237" ref-type="bibr">48</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Sulfones</td><td align="center" valign="middle" rowspan="1" colspan="1">1937 [<xref rid="B49-antibiotics-11-01237" ref-type="bibr">49</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1943 [<xref rid="B50-antibiotics-11-01237" ref-type="bibr">50</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1963 [<xref rid="B35-antibiotics-11-01237" ref-type="bibr">35</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Polypeptides</td><td align="center" valign="middle" rowspan="1" colspan="1">1939 [<xref rid="B51-antibiotics-11-01237" ref-type="bibr">51</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1941 [<xref rid="B52-antibiotics-11-01237" ref-type="bibr">52</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">N/A <sup>1</sup> [<xref rid="B25-antibiotics-11-01237" ref-type="bibr">25</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Salicylates</td><td align="center" valign="middle" rowspan="1" colspan="1">1940 [<xref rid="B53-antibiotics-11-01237" ref-type="bibr">53</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">1944 [<xref rid="B54-antibiotics-11-01237" ref-type="bibr">54</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1949 [<xref rid="B55-antibiotics-11-01237" ref-type="bibr">55</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Aminoglycosides</td><td align="center" valign="middle" rowspan="1" colspan="1">1943 [<xref rid="B56-antibiotics-11-01237" ref-type="bibr">56</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1946 [<xref rid="B57-antibiotics-11-01237" ref-type="bibr">57</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1946 [<xref rid="B58-antibiotics-11-01237" ref-type="bibr">58</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Phenazines</td><td align="center" valign="middle" rowspan="1" colspan="1">1943 [<xref rid="B59-antibiotics-11-01237" ref-type="bibr">59</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1962 [<xref rid="B60-antibiotics-11-01237" ref-type="bibr">60</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">2014 [<xref rid="B61-antibiotics-11-01237" ref-type="bibr">61</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Nitrofurans</td><td align="center" valign="middle" rowspan="1" colspan="1">1944 [<xref rid="B62-antibiotics-11-01237" ref-type="bibr">62</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1946 [<xref rid="B63-antibiotics-11-01237" ref-type="bibr">63</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1958 [<xref rid="B64-antibiotics-11-01237" ref-type="bibr">64</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Bacitracin</td><td align="center" valign="middle" rowspan="1" colspan="1">1945 [<xref rid="B65-antibiotics-11-01237" ref-type="bibr">65</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1948 [<xref rid="B66-antibiotics-11-01237" ref-type="bibr">66</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1949 [<xref rid="B67-antibiotics-11-01237" ref-type="bibr">67</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Cephalosporins</td><td align="center" valign="middle" rowspan="1" colspan="1">1945 [<xref rid="B68-antibiotics-11-01237" ref-type="bibr">68</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1945 [<xref rid="B68-antibiotics-11-01237" ref-type="bibr">68</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1967 [<xref rid="B69-antibiotics-11-01237" ref-type="bibr">69</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Amphenicols</td><td align="center" valign="middle" rowspan="1" colspan="1">1947 [<xref rid="B70-antibiotics-11-01237" ref-type="bibr">70</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1949 [<xref rid="B71-antibiotics-11-01237" ref-type="bibr">71</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1950 [<xref rid="B72-antibiotics-11-01237" ref-type="bibr">72</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Polymyxins</td><td align="center" valign="middle" rowspan="1" colspan="1">1947 [<xref rid="B73-antibiotics-11-01237" ref-type="bibr">73</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1948 [<xref rid="B74-antibiotics-11-01237" ref-type="bibr">74</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1960 [<xref rid="B75-antibiotics-11-01237" ref-type="bibr">75</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Enniatins</td><td align="center" valign="middle" rowspan="1" colspan="1">1947 [<xref rid="B76-antibiotics-11-01237" ref-type="bibr">76</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1968 [<xref rid="B77-antibiotics-11-01237" ref-type="bibr">77</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">N/A <sup>1</sup> [<xref rid="B78-antibiotics-11-01237" ref-type="bibr">78</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Tetracyclines</td><td align="center" valign="middle" rowspan="1" colspan="1">1948 [<xref rid="B79-antibiotics-11-01237" ref-type="bibr">79</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1948 [<xref rid="B80-antibiotics-11-01237" ref-type="bibr">80</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1953 [<xref rid="B81-antibiotics-11-01237" ref-type="bibr">81</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Diaminopyrimidines</td><td align="center" valign="middle" rowspan="1" colspan="1">1948 [<xref rid="B82-antibiotics-11-01237" ref-type="bibr">82</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1962 [<xref rid="B83-antibiotics-11-01237" ref-type="bibr">83</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1968 [<xref rid="B84-antibiotics-11-01237" ref-type="bibr">84</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Tuberactinomycins</td><td align="center" valign="middle" rowspan="1" colspan="1">1951 [<xref rid="B85-antibiotics-11-01237" ref-type="bibr">85</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1953 [<xref rid="B86-antibiotics-11-01237" ref-type="bibr">86</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1959 [<xref rid="B87-antibiotics-11-01237" ref-type="bibr">87</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Pleuromutilins</td><td align="center" valign="middle" rowspan="1" colspan="1">1951 [<xref rid="B88-antibiotics-11-01237" ref-type="bibr">88</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">2006 [<xref rid="B89-antibiotics-11-01237" ref-type="bibr">89</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">2008 [<xref rid="B90-antibiotics-11-01237" ref-type="bibr">90</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Macrolides</td><td align="center" valign="middle" rowspan="1" colspan="1">1952 [<xref rid="B91-antibiotics-11-01237" ref-type="bibr">91</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1952 [<xref rid="B92-antibiotics-11-01237" ref-type="bibr">92</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1952 [<xref rid="B93-antibiotics-11-01237" ref-type="bibr">93</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Nicotinamides</td><td align="center" valign="middle" rowspan="1" colspan="1">1952 [<xref rid="B94-antibiotics-11-01237" ref-type="bibr">94</xref>,<xref rid="B95-antibiotics-11-01237" ref-type="bibr">95</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1952 [<xref rid="B96-antibiotics-11-01237" ref-type="bibr">96</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1952 [<xref rid="B97-antibiotics-11-01237" ref-type="bibr">97</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Streptogramins</td><td align="center" valign="middle" rowspan="1" colspan="1">1952 [<xref rid="B98-antibiotics-11-01237" ref-type="bibr">98</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1962 [<xref rid="B99-antibiotics-11-01237" ref-type="bibr">99</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1977 [<xref rid="B100-antibiotics-11-01237" ref-type="bibr">100</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Thioisonicotinamides</td><td align="center" valign="middle" rowspan="1" colspan="1">1952 [<xref rid="B101-antibiotics-11-01237" ref-type="bibr">101</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1955 [<xref rid="B102-antibiotics-11-01237" ref-type="bibr">102</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1959 [<xref rid="B101-antibiotics-11-01237" ref-type="bibr">101</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Glycopeptides</td><td align="center" valign="middle" rowspan="1" colspan="1">1955 [<xref rid="B103-antibiotics-11-01237" ref-type="bibr">103</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1958 [<xref rid="B104-antibiotics-11-01237" ref-type="bibr">104</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1987 [<xref rid="B105-antibiotics-11-01237" ref-type="bibr">105</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Lincosamides</td><td align="center" valign="middle" rowspan="1" colspan="1">1955 [<xref rid="B106-antibiotics-11-01237" ref-type="bibr">106</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1963 [<xref rid="B107-antibiotics-11-01237" ref-type="bibr">107</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1967 [<xref rid="B108-antibiotics-11-01237" ref-type="bibr">108</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Cycloserines</td><td align="center" valign="middle" rowspan="1" colspan="1">1955 [<xref rid="B109-antibiotics-11-01237" ref-type="bibr">109</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1956 [<xref rid="B110-antibiotics-11-01237" ref-type="bibr">110</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1957 [<xref rid="B111-antibiotics-11-01237" ref-type="bibr">111</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Ansamycins</td><td align="center" valign="middle" rowspan="1" colspan="1">1957 [<xref rid="B112-antibiotics-11-01237" ref-type="bibr">112</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1961 [<xref rid="B113-antibiotics-11-01237" ref-type="bibr">113</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1969 [<xref rid="B114-antibiotics-11-01237" ref-type="bibr">114</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Fusidanes</td><td align="center" valign="middle" rowspan="1" colspan="1">1958 [<xref rid="B115-antibiotics-11-01237" ref-type="bibr">115</xref>,<xref rid="B116-antibiotics-11-01237" ref-type="bibr">116</xref>,<xref rid="B117-antibiotics-11-01237" ref-type="bibr">117</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1962 [<xref rid="B118-antibiotics-11-01237" ref-type="bibr">118</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1966 [<xref rid="B119-antibiotics-11-01237" ref-type="bibr">119</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Nitroimidazoles</td><td align="center" valign="middle" rowspan="1" colspan="1">1959 [<xref rid="B120-antibiotics-11-01237" ref-type="bibr">120</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1962 [<xref rid="B121-antibiotics-11-01237" ref-type="bibr">121</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1978 [<xref rid="B122-antibiotics-11-01237" ref-type="bibr">122</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Ethambutol</td><td align="center" valign="middle" rowspan="1" colspan="1">1961 [<xref rid="B123-antibiotics-11-01237" ref-type="bibr">123</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1962 [<xref rid="B124-antibiotics-11-01237" ref-type="bibr">124</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1969 [<xref rid="B125-antibiotics-11-01237" ref-type="bibr">125</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Quinolones</td><td align="center" valign="middle" rowspan="1" colspan="1">1962 [<xref rid="B126-antibiotics-11-01237" ref-type="bibr">126</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1963 [<xref rid="B127-antibiotics-11-01237" ref-type="bibr">127</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1966 [<xref rid="B128-antibiotics-11-01237" ref-type="bibr">128</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Phosphonates</td><td align="center" valign="middle" rowspan="1" colspan="1">1969 [<xref rid="B129-antibiotics-11-01237" ref-type="bibr">129</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1974 [<xref rid="B130-antibiotics-11-01237" ref-type="bibr">130</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1977 [<xref rid="B131-antibiotics-11-01237" ref-type="bibr">131</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Mupirocin</td><td align="center" valign="middle" rowspan="1" colspan="1">1971 [<xref rid="B132-antibiotics-11-01237" ref-type="bibr">132</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1985 [<xref rid="B133-antibiotics-11-01237" ref-type="bibr">133</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1987 [<xref rid="B134-antibiotics-11-01237" ref-type="bibr">134</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Lipiarmycins</td><td align="center" valign="middle" rowspan="1" colspan="1">1975 [<xref rid="B135-antibiotics-11-01237" ref-type="bibr">135</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">2009 [<xref rid="B136-antibiotics-11-01237" ref-type="bibr">136</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">2019 [<xref rid="B137-antibiotics-11-01237" ref-type="bibr">137</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Carbapenems</td><td align="center" valign="middle" rowspan="1" colspan="1">1976 [<xref rid="B138-antibiotics-11-01237" ref-type="bibr">138</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1983 [<xref rid="B139-antibiotics-11-01237" ref-type="bibr">139</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1986 [<xref rid="B140-antibiotics-11-01237" ref-type="bibr">140</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Monobactams</td><td align="center" valign="middle" rowspan="1" colspan="1">1981 [<xref rid="B141-antibiotics-11-01237" ref-type="bibr">141</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1984 [<xref rid="B142-antibiotics-11-01237" ref-type="bibr">142</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1984 [<xref rid="B143-antibiotics-11-01237" ref-type="bibr">143</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Oxazolidinones</td><td align="center" valign="middle" rowspan="1" colspan="1">1987 [<xref rid="B144-antibiotics-11-01237" ref-type="bibr">144</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1999 [<xref rid="B145-antibiotics-11-01237" ref-type="bibr">145</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">2001 [<xref rid="B146-antibiotics-11-01237" ref-type="bibr">146</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Lipopeptides</td><td align="center" valign="middle" rowspan="1" colspan="1">1987 [<xref rid="B147-antibiotics-11-01237" ref-type="bibr">147</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1999 [<xref rid="B148-antibiotics-11-01237" ref-type="bibr">148</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">2005 [<xref rid="B149-antibiotics-11-01237" ref-type="bibr">149</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diarylquinolines</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2005 [<xref rid="B150-antibiotics-11-01237" ref-type="bibr">150</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2008 [<xref rid="B151-antibiotics-11-01237" ref-type="bibr">151</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2014 [<xref rid="B61-antibiotics-11-01237" ref-type="bibr">61</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p><sup>1</sup> Not applicable&#x02014;clinical resistance is yet to be identified.</p></fn></table-wrap-foot></table-wrap></floats-group></article>